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ABSTRACT
Purpose: The sustainability of clinical pharmacogenomics requires further study of clinical
education on the topic, its effects on clinical workflow, and the responsibilities of different
providers for its delivery. Tools from the discipline of implementation science were utilized
herein to help achieve the purposes of the three studies. The broad purpose of this dissertation is
to advance the work of clinical pharmacogenomic implementation through a more rigorous
convergence with implementation science.
Methods: Three studies constitute the whole of this dissertation. The first is a scoping review
that provides a broad characterization of the methods utilized in available peer-reviewed
literature focusing on provider use of and experience with using pharmacogenomics in practice
or the study setting. The second study used semi-structured in-depth interviews to elicit strategies
and perspectives from leadership in current implementation programs using the Consolidated
Framework for Implementation Science (CFIR) Process Domain. The third used a crosssectional quantitative survey with experimental vignettes to explore the potential for pharmacistphysician collaboration using newly developed implementation science outcomes.
Results: The scoping review included 25 studies, with many focused on the interactions of
providers with clinical decision support systems and adherence to therapeutic recommendations
represented. Results from the interviews were extensive but several highlights included a focus
on understanding pharmacogenomic use prior to implementation, high-touch informal
communication with providers, and the power of the patient case. The survey analysis revealed
ii

that the primary care physicians believe that it is more appropriate to deliver clinical
pharmacogenomics when a pharmacist is physically located in a clinic and is responsible for
managing and modifying a drug therapy based on these results.
Conclusion: These three studies further the convergence of implementation science and genomic
medicine, with particular focus on pharmacogenomics and the foundational concept of
implementation science, sustainability. The scoping review should provide future researchers
with a landscape of available and previously used methodologies for interventional
pharmacogenomic studies. The interview results will help new implementers of
pharmacogenomics steer around avoidable hurdles or make them easier to address. The survey
results showcase the potential for pharmacist-physician collaboration in clinical
pharmacogenomics.
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INTRODUCTION
Precision medicine origins
In early 2015, the announcement of the Precision Medicine Initiative would make
precision medicine a nearly ubiquitous term across all sectors of the health care industry pushing
an innovative message. This program has since been renamed the “All of Us Research Program”,
and focuses on gathering the genomic, environmental, and lifestyle data on over one million
Americans across diverse populations (allofus.nih.gov).1 This National Institutes of Health (NIH)
program represents one of the largest efforts to integrate rapidly progressing genomic
technologies into research and accelerating medical innovation and breakthroughs. However, this
program has been preceded by numerous academic, industry, and government driven initiatives
pushing this science forward into clinical care.
Prior to genomic information being utilized in clinical care there have been several public
initiatives created to curate this complex data. One of these is ClinVar, a freely available archive
of information at the National Center for Biotechnology Information (NCBI) on the relationships
between genomic variants and phenotypes.2 A second program, ClinGen, was launched in 2013
to address the clinical relevance of the genomic variants identified in ClinVar.3 With the majority
of the 80 million genetic variants identified in the human genome having no clear link to human
disease or health implications, it was discovered that clinical laboratories may be interpreting the
importance of variants differently, potentially leading to inappropriate medical interventions.
ClinGen is focused on improving how new genomic discovery is used in clinical care by
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increasing communication between research institutions. The central questions for the project
were: “Is this gene associated with a disease?”, “Is this variant causative?”, and “Is this
information actionable?”.
Concurrently developed through requests from the National Human Genome Research
Institute (NHGRI) was the Clinical Sequencing Exploratory Research (CSER) program. This
program was initiated to create the evidence base for what appear to be the key challenges of
actually integrating genomic sequencing methods into clinical care across both adult and
pediatric patients.4 Several of these investigation sites focused cancer patients or those at an
increased risk of developing cancer, while others focused more on self-reported health patients
and those with other medical conditions. Not only was the CSER interested in addressing the
issues of generating genomic data and conducting the subsequent analyses, they also dedicated
resources to understand provider level education factors, patient and family communications, the
clinical utility of testing (ClinGen’s “Is this information actionable?”) and the ethical, legal, and
social implications (ELSI). The ELSI has become an important area of focus in the NHGRI’s
2020 strategic vision for genomics (https://www.genome.gov/27570607/strategic-planningoverview/).
While these aforementioned projects represent more sweeping initiatives related to
genomics, there also exist several other collaborative or consortiums focused on more specific
issues. The Electronic Medical Records and Genomics (eMERGE) Network was formed in 2007
and focused on exploring how the electronic health record (EHR) may be married with the
growing genomic data repositories, and how clinically relevant variants could be made
actionable through this to support clinical decision support.5 The work of eMERGE’s diverse
network allows for consolidation of genomic data across sites for comparison to already existing,
2

longitudinal phenotypic data from the EHR. This can lead to the discovery of novel variants in
the population, compared then to existing variants, leading to a final determination of those
clinically actionable and in need of being placed in the EHR.
Genomic medicine implementation and pharmacogenomics
The Implementing Genomics Into Practice (IGNITE) Network formed in 2013 takes the
logical next step in preparing the clinical environment for the inevitability of integrating new
patient-level genomic data.6 Health care research has been steadily moving towards an emphasis
on generating more real-world evidence of new health interventions. For real-world evidence to
actually exist, the practitioners and researchers the intervention affects must be effectively
prepared to use it. The work of IGNITE builds on the eMERGE work through point-of-care
integration of the data into the EHR and use of CDS tools to guide the clinician. The challenges
to genomic medicine most targeted by the IGNITE group include those that can be classified a
T3 and T4 translational research practices.7 These include improving patient outcomes and care
quality, evaluating the cost of different testing approaches, enhancing provider engagement and
education, and addressing the policy challenges of testing reimbursement and payer support.
The diversity of genomic technologies is both a barrier and facilitator to implementation
in clinical care. Genomic sequencing has accelerated with the development of massively parallel
sequencing techniques, and includes sub-applications of the technology such as exome
sequencing and multigene panels.8 Exome sequencing includes only those regions of the genome
that code for proteins (exons), and has been used more extensively in past years because of its
lower cost technical ability, yet there are limitations related to inadequate sequencing depths and
identifying genotypes that exist at specific single-nucleotide polymorphisms or SNPs outside of
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the exons.9,10 Multigene panels are typically aimed at specific genes where clinically significant
variants are known to exist and may be expressed in certain patient. One of the most common
historical uses of genomic sequencing has been the diagnosis of rare Mendelian disease, and is
typically indicated for those patients with a suspected monogenic disorder.11 These diagnoses
can help clinicians develop treatment plans and patients make personal decisions on family
planning. Additional applications can include screenings of partners prior to the conception of
offspring and genetic predisposition screenings for information on predictions of disease risk
based on genetics as well, giving clinicians another layer of phenotypic data for the patient.
Included in this last type of predisposition screening are predispositions related to
medication efficacy and safety based on genomics, which has become known as
pharmacogenomics. This will be the focus of the remainder of this dissertation.
Pharmacogenomics works through the identification of variants in the genome that exert some
influence on the effects of medication.12 Variations can occur in the absorption, distribution,
metabolism, excretion (ADME) genes, those that affect the medication’s pharmacokinetics or the
pharmacodynamic genes that modify the target or pathway of the medication in the body.
The pharmacogenomic implications for a patient can apply either to those variants
somatically acquired, typically cancer or infectious disease, and variants originating in the
germline DNA, that sequence with which you are born. Pharmacogenomics has been the leading
the way in operationalizing the benefits of precision medicine. A seminal systematic review in
2001 explored the role for pharmacogenomics in potentially reducing the number of adverse
drug reactions, a leading cause of death then and still today.13,14 Their results showed about 60%
of drugs cited in ADR studies at the time had at least one drug-metabolizing enzyme that was
genetically encoded with a variant known to cause poor metabolism.
4

Metabolism classification for these enzymes encoded in the germline has become a key
action item from patient’s specific diplotypes, one haplotype from each parent.15 The CYP450
gene superfamily was an early pharmacogenomic discovery and is involved in the metabolism of
about 75% of commonly prescribed drugs.16 The polymorphic drug metabolism enzymes
associated with CYP450 genes are prone to variations that ultimately affect how a drug’s
pharmacokinetics act upon the patient, and the subsequent safety and efficacy to the patient. The
phenotypic definitions of the various metabolizer statuses recently reached consensus through
work by the Clinical Pharmacogenetics Implementation Consortium (CPIC).17 We will discuss
CPIC in greater detail below. Standardization of these terms is crucial for the reporting and
sharing of results across laboratories and EHRs. The final terms are created based on a
combination of allele functional status, which include increase, normal, decreased, and no
function.18 The metabolizer terms include ultrarapid, rapid, normal, intermediate, and poor.
Those of most interest clinically are the ultrarapid metabolizers, which include two increased
function alleles or more than 2 normal alleles, and poor metabolizers, which include
combinations of no function alleles and/or decreased function alleles.18
Genotyping of tumors or infectious diseases, also known as somatic testing, is another
way pharmacogenomics has been operationalized in precision medicine.12 An ideal state for
‘precision medicine’ might be circumstance where every medication based treatment is
developed specifically for a biomarker(s) known to be causing the disease. Although not there
yet, tumor biomarkers appear to be carving a path where companion diagnostic tests can be used
to guide the decision to use a specific anti-cancer agent targeted to a specific mutation. This is
intended to interfere with the tumor’s function to inhibit growth and progression, leading to
quicker resolution of the disease.19 Some of the most well-known mutations are the HER2 target
5

for breast cancer, EGFR for non-small cell lung cancer, and BRAF for melanoma.20-22 Germline
pharmacogenomics also has a role in preventing adverse events for several commonly used
chemotherapy agents that may require dose reductions or drug switches to avoid potentially
devastating consequences. The TPMT, DPYD, and UGT1A1 genes are several that contain
toxicity biomarkers variants.19
Movement towards implementing pharmacogenomics in clinical practice, similar to
genomics more broadly, has been driven by academic medical centers funded from public
resources such as the NIH. Early on, after the completion of the Human Genomic Project the
Pharmacogenomics Research Network (PGRN) began receiving grants from the National
Institute of General Medical Sciences to study how genetic variation contributes to
interindividual differences in responses to medication.23 The eMERGE network mentioned
previously received grants from the NHGRI to dedicate part of their work to coupling the EMR
with actionable pharmacogenomic data.24 Since then the number of supported collaborative,
consortiums dedicated to facilitating the implementation of pharmacogenomics have steadily
grown. Two highly influential, and coordinated, efforts have been The Pharmacogenomics
Knowledgebase (PharmGKB) and CPIC, which was briefly mentioned earlier. PharmGKB
works through a process starting with extracting knowledge from pharmacogenomic literature on
the associations between variants and drugs to determine those to be “very important
pharmacogenes (VIP)”. These lead to pharmacogenomic summaries based on genotypes with
different levels of evidence.25 All this knowledge can then filter into implementation projects and
also to CPIC, whose primary responsibility is to turn genotypes into meaningful phenotypes that
a clinician can act on. Both PharmGKB and CPIC annotate their levels of evidence across the
gene-drug pairs they have evaluated. The highest level of evidence for PharmGKB is level 1A,
6

which is defined as “Annotation for a variant-drug combination in a CPIC or medical societyendorsed PGx guideline, or implemented at a PGRN site or in another major health system”
(pharmgkb.org/page/clinAnnLevels).26 CPIC has designated its levels for gene-drug pairs as
either: A, B, C, or D. Level A indicates that “genetic information should be used to change
prescribing of affected drug”, while level B indicates that genetic information could be used to
change prescribing because alternatives are likely as effective and safe as non-genetically based
dosing. Lower levels, C and D, indicated that there are no recommended prescribing actions
(cpicpgx.org/prioritization/#flowchart).27 CPIC uses these levels to prioritize their clinical
prescribing guideline development, of which there are 35 currently published and more in
progress. These guidelines are not intended to help clinicians order a test, rather how to use the
results when they become available. More recently, the Pharmacogene Variation (PharmVar)
consortium was formed to address the need for a more systematically maintained pharmacogene
nomenclature (or language) system as the number of variants discovered continues to grow.28
The work of these organizations has served as a crucial foundation for the
implementation of pharmacogenomics in the sphere of academic medicine. Efficient and
appropriate pharmacogenomic implementation, with a mindset of sustainability, should be the
ultimate goal of using public resources to fund discovery such as this. Two of the networks
discussed, IGNITE and eMERGE, are actively testing implementation strategies and sharing
data. Additionally, PGRN organized the Translational Pharmacogenetics Project (TPP) in 2011
with the stated goals of: harnessing multidisciplinary team expertise and institutional investment,
implement routine gene-based drug dosing and selection, and to identify the best implementation
and dissemination practices to address remaining barriers.29 Over a dozen metrics were reported
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by the TPP covering everything from the triggers to prompting a test order to the estimated
turnaround time, and the roles that different providers play in the implementation.
The IGNITE network set up an internal working group dedicated to pharmacogenomics
in 2015.30 This group set out with to engage both funded network sites and its affiliate members,
some of which being non-academic. Measuring the impact of genotype-guided therapy on
patient-related outcomes has become the central goal of the institutions involved. Spearheaded
by the University of Florida, the group intends to share and disseminate data on effective and
non-effective strategies from their individual projects, as well as metrics related to the health
care costs involved in the strategy.30 In this model, more pharmacogenomically-mature
institutions have the ability to share their best practices with newer entrants into the science, thus
updating prior beliefs and improving the efficiency.
Similarly to IGNITE, the eMERGE network initiated a pharmacogenomic specific
project, eMERGE-PGx.31 The design of this project was focused on a particular strategy of
testing known as preemptive pharmacogenomics, that is, the genotyping or sequencing of a
patient prior to diagnosis enabling first point-of-care actionability. This technique was already
being implemented among some institutions; however reactive testing still remained the most
utilized.32 eMERGE-PGx had three objectives: sequence 84 proposed pharmacogenes in 9,000
patients likely to be prescribed an implicated drug within one to three years, integrate the
clinically-valid results into an EHR with the appropriate decision support and assess the
outcomes, and develop a repository for those variants with unknown significance back-linked to
the clinical phenotypes in the EHR.31 Early results from approximately 5,000 subjects showed
96.19% of samples had a CPIC level A actionable variant. These high probabilities were also
found in an external validation cohort of more than 1,000 patients in a tertiary medical center. A
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novel disease-drug association tool was developed to map drugs to distinct diseases, then
pharmacogenomically annotated. Ninety-percent of the top 21 diseases in this population and
more than 93% of patients could be treated with more than one medication with actionable
pharmacogenomic information.
Many of opportunities afforded to the implementers of pharmacogenomics, and noted
successes, were enabled by high levels clinical and leadership support at the institution, as well
as extensive external funding. The next frontier in the implementation of pharmacogenomics is
to address the unique challenges of implementation into ambulatory care settings. These include
fewer financial resources, greater fragmentation, and a workforce less familiar with
pharmacogenomics than those described in these numerous networks herein.33,34 The Centers for
Disease Control and Prevention (CDC) Office of Public Health Genomics has weighed in, stating
we must understand “what factors contribute to the success or failure of a genomic application
within a particular setting” (blogs.cdc.gov/genomics/2017/11/27/if-you-build-it/).35 There will
always be variability in any broadly defined setting, such as tertiary academic or primary care,
but the differences between will typically exceed those within.
Given the breadth of diversity in the delivery of health care, approaching implementation
of pharmacogenomics in new settings deserves the same level of scientific rigor that allowed it to
progress to its current point. The growing field of implementation science may offer this rigor
through its theories, methodologies, and frameworks.36 The need for implementation science was
born out of issues in both time it took clinical evidence-based practices to reach usage and the
total proportion that ever did, average of 17 years and 50%, respectively.37 Though its theories
and constructs have applications in other industries such as technology or transportation, the
original conceptualization for implementation science was health care.37 A commonly used
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definition of the science is “the scientific study of methods to promote the systematic uptake of
research findings and other evidence-based practices into routine practice, and, hence, to
improve the quality and effectiveness of health services”.37 Implementation science is most
commonly organized into five foundational concepts: 1) diffusion, 2) dissemination, 3)
implementation, 4) adoption, and 5) sustainability.38 These concepts are to be viewed as part of
feedback loop with the achievement of sustainability leading to the ability to diffuse new ideas,
behaviors, and practices. Effective implementation is at the center of these five concepts as each
should be considered during the design process of bringing an evidence-based intervention or
practice into usage.36 As a relatively new science, it is not without its own set of challenges that
must be overcome. Some of these include: a lack of common language (a continuing issue in
genomics and pharmacogenomics), short-termism, and a lack of embedded evaluation plans.
These last two have been highlighted for their application to this dissertation. Short-termism can
parallel with the last ‘foundation concept’ of sustainability, and a ‘lack of embedded evaluation
plans’ helps illuminate that not only are intervention outcomes important, but also the need to
develop implementation-specific outcome measurements.
The foundational concept of sustainability has received increasing attention as one of the
most important, yet more misunderstood concepts of implementation science.39 In fact, recent
work attempted to unify the discussion on sustainability through a paper on the development of a
comprehensive definition.40 Although commendable, in the spirit of Proctor et al. sustainability
is likely more complex than only one definition.39 How one defines sustainability in an
individual study should be explicitly rationalized or come from a previous publication.39 The
contradiction between this and the just mentioned ‘lack of common language’ exhibit the
complexities implementation science researchers are facing. However, this Proctor et al. paper
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represents a seminal work to identify the most important issues for research in sustainability. A
concept-mapping approach was used that are encompassed in three overarching domains: 1) an
agenda unified through answering the high priority research questions on sustainability 2)
methodology advancement for sustainability research 3) and advance infrastructure to support
this research. These domains are characterized by 91 unique statements within 11 unique
conceptual clusters within five larger clusters.39
Methodological advancement of sustainability will require the application of individual
frameworks in study design and execution. A systematic review of the sustainability landscape
revealed 62 publications where a unique sustainability approach was used. These include 32
frameworks, 16 models, 8 tools, 4 strategies, 1 checklist, and 1 process.41 The obvious
observation is that the selection of a framework or model can overload the researcher’s choiceset. However, taking a high-level view of multiple disciplines can train the eye to identify where
there are overlays in the needs of the discipline being applied to the sustainability framework, as
well as ways in which the framework itself can address issues within its own parental discipline
of implementation science.
The Dynamic Sustainability Framework (DSF) is a framework built around seven major
tenets the authors recommend for explicit testing (Table 1) and a visual model (recreated in
Figure 1).42 The DSF was designed based on previous literature that put forth an alternative
conceptualization of sustainability as a cyclical “change process” that provides adaptability in
pre-implementation stages such as planning and organizational support rather than an outcome or
metric of successful implementaiton.43,44 Sustainability is further operationally defined in three
more specific constructs: maintenance, institutionalization, and (infrastructure) capacity
building.38 The sustainability planning model operationalizes capacity building as both physical
11

and human infrastructures: structures and linkages, champions and leadership, resources, policies
and procedures, and expertise.43,45 The operationalization of capacity building as a human
infrastructure is an important development for this dissertation.
Table 1. Tenets of the Dynamic Sustainability Framework
1

•

Interventions need not (and should not) be optimized prior to implementation

2

•

Interventions can be continually improved, specific to each setting

3

•

Ongoing feedback is essential and should be measured over time

4

•

More diverse/complex populations does not mean an inevitable loss in benefit

5

•

Strong ‘fit’ is essential, but it will likely change over time

6

•

Organizational learning should be at the core

7

•

Stakeholder involvement throughout all processes

Figure 1. Recreation of the Dynamic Sustainability Framework
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Highlighted throughout the DSF is an emphasis on ongoing adaption and evaluation of an
intervention with the goal of continuous improvement to determine its optimal ‘fit’ across
various ‘practice settings’. Designing implementations with a DSF-type mindset may make
headways in addressing the previously mentioned, ‘lack of embedded evaluation plans’
challenge for implementation science. As part of this, valid and reliable outcome measurements
for implementation research are being developed. A systematic review found 104 measurement
instruments in a core set of outcomes previously identified: acceptability, adoption,
appropriateness, cost, feasibility, fidelity, penetration, and sustainability.46,47 Approximately twothirds measured acceptability and adoption, with all others having less than 10 measurements.
Psychometric strength and quality were also highlighted as being underdeveloped. In response, a
follow-up study by some of the authors developed, and psychometrically assessed, three new
measures with promising psychometric properties: Acceptability of Intervention Measure (AIM),
Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM).48
These measures are utilized in the manuscript and described in Section III.
Calls to begin cultivating a formal relationship between implementation science and
precision medicine, as well as the learning health system, have been made in the past several
years.49 The National Academies of Sciences, Engineering, and Medicine recently held a
workshop entitled “Applying an Implementation Science Approach to Genomic Medicine”. The
report emphasizes a focus on methods to encourage wider participation from minority and
disadvantaged populations, evidence building and clinical research done in parallel (aspects of a
learning health care system), and a focus on genomic applications to improving population
health.50 The lack of implementation science frameworks in the National Institutes of Health’s
grant portfolio for genomic medicine may be a contributor to these calls. From 2012 to 2016,
13

only 1.75% of genomic related grants included the formal use of an implementation science
framework.51 This equates to a total of four grants, all of which used the same framework,
Rogers’ Diffusion of Innovation.51 This seminal work by Everett Rogers provided the field of
implementation science with several key components of innovation diffusion including
perceptions of the innovation itself such as compatibility, the degree of innovativeness in the
adopter, the environment of the adopter and the systems in place in the environment, and lastly,
the actual process of adoption.52 Implementation science has built on the breadth of Rogers’
ideas and created immense depth, as evidenced by the DSF, into each of these components, as
well as creating new layers of breadth with frameworks such as the Consolidated Framework for
Implementation Research (CFIR) which will be discussed below.53 Rogers’ original work in
agriculture has been extrapolated to countless scientific disciplines and thus, this work, and
others utilizing the discipline of implementation science, should be read not only as contributing
to their specific fields but as important additions to the general pursuit of evidence-based
scientific practice.
In addition to the lack of implementation science grants, the CDC’s Public Health
Genomics Knowledge Base was used to identify published literature where implementation
science has been applied to genomics medicine. Although the findings showed a total of 283
articles published in 2014, the inclusion criteria did not specify that a formal implementation
science approach be taken, rather that the studies “contributed to our understanding of the
implementation of genetic/-omic testing…”. In fact, what was discovered was that very few
studies actually incorporated a theoretical framework from implementation science, any measure
of sustainability, or capacity building (a key component of sustainability).38,54
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Two working groups from IGNITE, Common Measures and Sustainability, recently put
the field of genomics in more rigorous alignment with implementation science, and its
foundational concept of sustainability.53,55 The Common Measures group utilized the CFIR, one
of the most robust widely used frameworks of implementation science.53 This framework is
composed of five domains containing 39 constructs or sub-constructs and was built from a large
scale evaluation of available implementation science theories, with an end goal of producing a
pragmatic way to improve this science. The CFIR now has its own dedicated website
(cfirguide.org) which provides both quantitative and qualitative data collection tools, analysis
methods, and interpretation resources.
Though the IGNITE work did not specify pharmacogenomics, many of the takeaways are
logically applicable to it. The working group evaluated the 39 constructs of the CFIR for their
contribution and importance to genomic medicine.45 The 10 highest-ranking constructs were
included in the final list, with the intention to develop data collection tools for the network. Table
2 provides a list of these constructs. The construct “patient characteristics” was included as highpriority although it is a non-CFIR construct. The authors found that the CFIR lacked “welldefined representation of patient-related domains”. While patients do represent a critical aspect
of implementing a new intervention effectively, they believe that this impact is less influential
than the clinicians and institutional leadership when it comes to initial implementation
successes.45
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Table 2. High-priority CFIR and *non-CFIR constructs identified by IGNITE CMG
Knowledge
and beliefs
about the
intervention

Self-efficacy

Implementation
climate

Readiness for
implementation

Relative
Advantage

Cost

Engaging

Executing

Reflecting &
Evaluating

Patient
characteristics*

An effort was made to identify existing measurement tools for these 10 constructs, and to
move forward with the development of novel ones where no existing measures had been
developed. While many of the ‘patient characteristics’ sub-constructs had reliable and valid
measurement tools already in place, most of the high-priority constructs from CFIR did not. This
led to an initiative to create these measures, including the pre-implementation provider survey
among others freely available in the IGNITE Spark Toolbox (ignite-genomics.org/sparktoolbox/researchers/). The CFIR has also been used in other genomic-focused papers. For
example, Lynch Syndrome screening is a condition that can raise the lifetime risk of developing
colorectal cancer by as much as 4%, but has faced heterogeneous barriers to implementation that
the authors believed implementation science, and the CFIR could address.56,57 Though not an
explicit test of the constructs, the paper focused on Lynch Syndrome matched relevant domains
of the CFIR with potential applications for Lynch Syndrome, somewhat similar to the IGNITE
work with the framework. The CFIR, and in particular the Process domain, guided the
development and data collection of the study described in Section II of this dissertation. The
Process domain of the CFIR contains four constructs (Planning, Engaging, Executing, Reflecting
& Evaluating). The Engaging constructs is made of up of six sub-constructs (formally appointed
implementation leaders, opinion leaders, champions, key stakeholders, innovation participants,
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and external change agents). In their original work, the authors of the CFIR describe the
constructs of the Process domain as the “essential activities of implementation processes that are
common across organizational change.”53
In a complementary work, the IGNITE Sustainability Working Group identified 28
constructs most important in sustainability of genomic medicine.55 Again, these results apply to
genomics as a whole, but can be logically extrapolated to pharmacogenomics. These 28
constructs were arrived at by crossing sever key drivers of sustainability elicited from an openended survey with principal investigators and working group chairs within IGNITE. The second
survey collected a ranking of these drivers with applications across patient, provider, payer, and
government stakeholders. Table 3 shows the key drivers.
Table 3. Key drivers of genomic sustainability

Key Drivers

Infrastructure (EHR,
CDS, lab, manufacturers,
community)

Economic
measures

Clinical
evidence/effectiveness

Regulatory/legal

Research/development

Workforce
impact

Education

The top results, those identified as the top five most important of the second survey were
(1) expanded genomic education, (2) availability of clinical decision support (CDS) tools, (3)
formal recognition of economic data guiding reimbursement decisions (4) the impact of
integrating genomic information into workflow, and (5) need for reimbursement decisions and
prior authorization regimes. As one can see, these constructs can be easily split into two groups:
those that directly affect the provider in the context of delivering genomic medicine and those
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that affect reimbursement and coverage policies to pay for genomic testing. The former will be
the focus herein.
A recent review of the pharmacogenomic landscape led by many leaders in the field
includes brief reflections on things learned, recommendations on improvements, and future
directions.58 Included in these reflections are several of the same things that IGNITE found to be
important to sustainability: workforce education, clinical tools for genomic implementation of
pharmacogenomic variants, availability of pharmacogenomic testing (often driven by
reimbursement), and others. Some of the most pressing issues noted by physicians specifically
are the development of effective clinical decision support tools and educational training
mechanisms.59
One important thing discussed in this review that appears to have been missed by the
IGNITE Sustainability group was the importance of stakeholder alignment and transdisciplinary
teams (interdisciplinary or multidisciplinary could be used). They list the full gamut of potential
partners, from other clinicians to patients to payers to engineers etc. Set forth by the TPP, the
implementation of pharmacogenomics was intended to be a multidisciplinary effort, leveraging
the expertise of various clinicians and researchers. Clinical collaboration in pharmacogenomics
involving the pharmacist has been a particularly important component of its delivery.60-62 Several
pharmacogenomic implementation sites have been initiated and driven by pharmacists and
pharmacy departments. These include St. Jude Children’s Research Hospital, a co-principal
investigator of the CPIC grant, and the University of Florida, which has led the efforts of the
IGNITE Pharmacogenomics working group.60,61,63
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Appropriate education and thus the ability to confidently apply pharmacogenomics to
clinical care appear to be lacking among both types of providers.34,64,65 Those physicians that
have been part of one or more of the pharmacogenomic initiatives described throughout here
have reported more favorable views toward genetic testing applications and a better sense of
preparedness.59 These results would likely be similar when comparing pharmacists involved in a
pharmacogenomic initiative or not. The collaboration of pharmacists may well provide a set of
complementary skills, including advanced training in the pharmacokinetics and
pharmacodynamics that apply so importantly to pharmacogenomics.66 Formal mechanisms such
as collaborative practice agreements (CPAs) and collaborative drug therapy management
(CDTM) programs may be important to creating the appropriate infrastructure to enable this.
CPAs and CDTMs expand the role of the pharmacists’ involvement with the patient through a
team-based approach, and working in a defined protocol that can include assessments,
counseling, ordering diagnostics, and managing the patient’s drug regime.67 Several studies have
illuminated the benefits of pharmacist involvement in the patient care team and the positive
outcomes across the spectrum, from clinical to humanistic.68-70 These successes in
interdisciplinary environments and a well-primed skill set to engage with pharmacogenomics
make this a logical investigation.
Given that most health care delivered in the US is not done at an academic institution,
there must be greater consideration of how pharmacogenomics can be successfully implemented
into ambulatory care, thus sustaining it beyond the externally-funded academic center, and
achieving those goals that the National Academies stressed implementation science and
genomics should address. Although sustainability may be difficult to define, the definition used
in the DSF, taken from Rabin et al., fits this current issue quite nicely: “to what extent an
19

evidence-based intervention can deliver its intended benefits over an extended period of time
after external support from the donor agency is terminated”.38
This work is organized in three sections all relevant to the above discussion. Framed by
implementation science and the foundational concept of sustainability this dissertation sought to
achieve three goals:
1. To provide a characterization of the nature and extent of the peer-reviewed
literature on the prospective and retrospective experiences with and actions of
health care providers when using pharmacogenomic information through a
scoping review. This work is framed around a core research question developed
from several tenets of the DSF and constructs related to the sustainability of
genomic medicine.
2. Elicit the experiences of early adopter leadership in pharmacogenomic
implementation through the questions posed by the CFIR Process domain. The
majority of the constructs in the Process domain were identified as high-priority
constructs for genomic medicine. Qualitative in-depths interviews served as the
data collection methodology.
3. To assess the perceived acceptability, appropriateness, and feasibility of
delivering pharmacogenomic in primary care through scenarios of a formal
physician-pharmacist collaborative practice environment. A factorial vignette
analysis manipulated scenarios of collaboration and other variables important in
the considerations of pharmacogenomic testing.
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SECTION I.
DECISION MAKING IN CLINICAL PHARMACOGENOMICS:
A SCOPING REVIEW
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1. BACKGROUND
Barriers to the scale up and spread of pharmacogenomics in clinical practice have been
thoroughly discussed over the past decade.1-4 While many of these barriers have been addressed,
numerous obstacles persist that preclude the successful application of clinical pharmacogenomics
beyond current institutions enabled by extramural or internal financial support. These obstacles
include an underdeveloped clinical decision support infrastructure, lack of third-party payer
coverage policies and reimbursement, and limited clinician and patient understanding.1,5-9
Several of these barriers were also highlighted in a recent work from the Implementing
Genomics into Practice (IGNITE) consortium, which ranked 28 important constructs for the
sustainability of genomic medicine.10 Interestingly, three of the top five ranked constructs (1, 2,
and 4) focused on provider needs and included: (1) expanded genomic education, (2) making
clinical decision support (CDS) tools available, and (3) integrating genomic information into
workflow.
A casual scan of the literature reveals numerous descriptive or cross-sectional studies
aimed at assessing the attitudes of providers toward pharmacogenomics. The descriptive papers
seen throughout the literature come, in large part, from the implementation initiatives established
at numerous academic hospitals across the US and abroad.11-14 Cross-sectional survey work
largely focuses on the attitudes, awareness, and concerns of clinical respondents regarding
pharmacogenomics. Furthermore, the literature finds that most have positive views of
pharmacogenomics, yet feel unprepared to deliver it practice.6,15-18 These studies highlight the
need for further education and intervention. While these papers are helpful in understanding the
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nuances and considerations necessary to establish a pharmacogenomic program, they typically
do not include a measurement or assessment of the intervention’s impact on those delivering it to
patients. However, the fact that this barrier continues to persist indicates that there is likely a
dearth of studies that actively measure provider response to using pharmacogenomics in clinical
workflow, or assessing experiences following actual clinical usage of such pharmacogenomic
information.
Real-world assessments and intervention-based studies are crucial as they provide
actionable insights to others either currently using or planning to use clinical pharmacogenomics
for patient care. The Dynamic Sustainability Framework (DSF) emphasizes the idea of ongoing
evaluation and adaptability of an intervention to achieve the goal of continuous improvement.19
Two tenets of the DSF, the continual improvement of the intervention and a focus on collecting
ongoing feedback about the intervention fold together the importance of measuring actual use of
an intervention and its impact on the sustainability of the intervention long-term.19 Learnings and
processes from the continuous quality improvement (CQI) literature combined with the rigor of
more evaluative research methodologies can lead to a better understanding of what changes are
effective in improving clinical delivery of pharmacogenomics while developing generalizable
methodologies for application in other settings.
With these considerations, our review is focused on answering the following research
question: How have the prospective or retrospective experiences and actions of prescribers,
pharmacists, or genetic counselors been measured when using pharmacogenomic information in
either real-world practice or a hypothetical research setting? The current objective of this review
is to provide a characterization of the nature and extent of peer-reviewed literature that is
applicable to the stated question. A scoping review was the appropriate review methodology as it
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aims to assess the extent, range, and nature of evidence to summarize heterogeneous methods or
disciplines, without pursuing a quality assessment of the literature.20
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2. METHODS
To increase the methodological transparency and uptake of these findings, the recent
checklist extension by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) published for scoping reviews (PRISMA-ScR) was used throughout this study.21
Protocol and Registration
A registered protocol was not developed prior to beginning the search of the literature.
However, the PROSPERO international prospective register of systematic reviews was searched
and there was no registered protocol when this project began in December of 2018 that exhibited
similarities in research objective or design.
Eligibility criteria
Detailed inclusion and exclusion criteria were developed prior to the first screening of the
search results. To be included in the review, papers must include an outcome that measures the
experiences of or action by a prescriber (physician or advanced-practice provider), pharmacist, or
genetic counselor when engaged in an actual or hypothetical scenario involving
pharmacogenomic testing. Published papers that were descriptive of an implementation project
and included provider elements yet do not include formal data collection methods were excluded.
Table 1 fully describes the inclusion and exclusion criteria.
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Table 1. Inclusion/exclusion criteria
Peer-reviewed literature in pharmacogenomics that evaluates the clinical
professional’s experience or action taken when using pharmacogenomic
Inclusion

information for clinical decision making

criteria
At least 50% of the data must come from responses or decisions made by
physicians (MD/DO), pharmacists (RPh/PharmD), or genetic counselors (CGC).
Studies that do not clearly state respondents have used or are using
pharmacogenomic information. This includes any study that is descriptive,
anecdotal, or opinion in nature.
Studies published that only include as respondents: patients, advanced practice
Exclusion non-physician providers (nurse practitioners/physician assistants), health
criteria

profession students, or nurses.
Studies not primarily focused on pharmacogenomics
Studies published before the year 2000
Studies published in a language other than English

Information sources and search
In December of 2018, potentially relevant papers were searched in the both the
MEDLINE® and Embase® bibliographic databases. MEDLINE® uses the MeSH® (Medical
Subject Headings), Embase® uses Emtree®. Search strategies were developed by the lead author
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and refined through discussion with other authors. Search results were exported into Microsoft
Excel® and duplicates removed. Microsoft Excel® was used to parse out MEDLINE® studies that
were duplicated and those that were unique from the Embase® search.
A total of 537 studies were pulled from MEDLINE®. The search of Embase® produced
201 studies unique to the Embase® library, and 241 unique studies that were not included in the
results of the MEDLINE® search. The Embase® library searches MEDLINE® in addition to its
own database. Appendix 1 provides the full search string for each database.
Selection of sources of evidence
Two authors (NK and TD) independently and iteratively reviewed titles and abstracts,
then full papers, making decisions to include or exclude at each stage. At the completion of each
stage the selecting authors discussed their assessments and came to consensus on the studies to
be included. Prior to beginning the selections, a screening form was developed and agreed upon
by the authors.
Data charting and data items
The data charting process used the STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology) checklist to determine which variables to extract from
the included studies. A data-charting form was developed by the lead author and shared with a
co-author (TD). Each author (NK and TD) took half of the included studies and independently
charted the data using this form.
In line with the PRISMA-ScR checklist, items 9, 11, and 12 of STROBE will be excluded
from the data charting process. These items correspond to sections usually absent from scoping
reviews and did not add to answering the stated research questions. Final variables included from
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the data abstraction were author and publication year, study location, research aims, study design
and methods, population and setting, outcome(s) of interest, and major findings. Table 2 is the
subsequent result of this extraction.
Synthesis of results
Lastly, two authors (NK and MR) performed an inductive content analysis of the study
design and study methods, as well as the major findings variables from each included article to
structure the scoping review findings. In line with the language of the research question, the
organization of the findings was determined according to the methodology driving the study. The
goal of this analysis was to come to consensus on the number of major methodological groupings
and the nature of the methods therein.
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3. RESULTS
Figure 1 below provides an overview of the number of studies screened, determined

Identification

eligible (with reasons for exclusion at each stage), and then included in the review findings.

Records identified through
database searching
(n = 1065)

Duplicates removed (n = 86)

Included

Eligibility

Screening

Records excluded, with first
reason (n = 890)
- Descriptive, review, or
opinion
(n = 553)
- Not pharmacogenomics (n =
153)
- Not a physician, pharmacist,
or genetic counselor majority
(n = 67)
- Language other than English
(n = 21)
- Published before 2000 (n = 8)
- Other (n = 85)

Title/abstract screened
(n = 979)

Full-text articles assessed for
eligibility
(n = 89)

Full-text articles excluded, with
primary reason (n = 64)
- No actual or hypothetical
intervention with or use of
pharmacogenomic information
(n = 44)
- Descriptive, review, or
opinion (n = 15)
- Not a physician, pharmacist,
or genetic counselor majority
(n = 5)

Studies included in extraction
(n = 25)

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram
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Characteristics of sources of evidence
A total of 25 studies underwent complete data extraction. Most studies (76.0%) were
from North America.22-38 Two studies (8.0%) were conducted in both US and international
settings,39,40 and the remaining were strictly conducted in strictly international settings (24.0%).
All studies except for two came from the US and Europe.
Most of this research was quantitative in nature (80.0%).22,24,25,28-33,35,39-44 Only three
studies were strictly qualitative in nature27,36,45 and two used a mixed-methods approach.23,26
Study designs ranged from cross-sectional surveys and in-depth interviews to hypothetical
clinical case scenarios and timed information-seeking exercises with subjects. One study took a
quasi-experimental approach.25 As outlined in the inclusion criteria, the majority of study
participants were physicians, pharmacists, or genetic counselors. Among the 25 studies, almost
all (96.0%) were categorized as majority physician23,25-27,29,31-33,35,36,39-45 while only one study
was solely pharmacist.28
In a somewhat blended approach, the primary outcome for four physician respondent
studies (16.0%) was adherence to therapeutic recommendations from either a pharmacist or
pharmacist-led surveillance service.22,24,30,34 Three additional studies tracked the therapeutic
action of a prescriber based on CDS support alerts or another return of results methods.37,38,46
None of the 25 studies included in the scoping review focused on genetic counselors.
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Table 2. General characteristics of studies included in the review (n = 25)
Characteristics

n

%

North America

20

80.0

Europe

6

24.0

Oceania

1

4.0

2015 – 2018

17

68.0

2010 – 2014

7

28.0

2005 – 2009

1

4.0

2000 - 2004

0

0.0

Quantitative

17

80.0

Qualitative

3

12.0

Mixed Methods

2

8.0

Hypothetical clinical case scenarios

9

40.0

Real-world studies on prescribing/testing decisions

7

28.0

Cross-sectional quantitative surveys

5

16.0

Cross-sectional qualitative interviews

3

12.0

Quasi-experimental

1

4.0

Region of origin*

Years published

General methodology

Study design

* Total equals more than 100% due to multi-country studies included
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Results of individual sources of evidence
Table 3 provides an evaluation of each study across all included variables for data
extraction. The qualitative content analysis of the study design and methods section revealed five
major methodological approaches: hypothetical clinical case scenarios, real-world studies
evaluating prescriber response to recommendations or alerts, cross-sectional quantitative
surveys, cross-sectional qualitative surveys/interviews, and a quasi-experimental real-world
study. In the following sections, each methodological approach will be defined with appropriate
sub-sections and aims identified, and a brief mention of major study findings will be provided.
Table 3. Peer-reviewed articles included in the scoping review
Author and
Publication
Year

Study
Location

Research Aims

Study Design and

Population and

Outcome(s) of

Methods

Setting

Interest

Major Findings

Bain et al.

United

To determine the

Prospective

The practice

Rates of

Eighty-nine percent

2018

States

feasibility of

evaluation of the

setting in which

prescribers'

of pharmacist

implementing a

implementation

this evaluation

acceptances of

recommendations

pharmacist led

processes in PACE.

was made was a

the PGx

were accepted by

PGx service for

This included

centralized

consultation

the referring

the Program of

reviewing policies

pharmacy in

recommendation

prescriber. 100% of

All-Inclusive

and procedures,

New Jersey that

s, when feasible.

recommendations

Care for the

observations

services 15-

were accepted in the

Elderly (PACE).

documented by the

20% of PACE

categories: continue

pharmacists,

participants in

drug (no change),

prevalence of genetic

21 states. PGx

consider drug dose

variants, and drug-

consultations

adjustment, and

gene interactions,

were led by two

consider drug

descriptive

senior

regimen change.

categorization of the

pharmacists and

38.5% of

types of pharmacist

a pharmacy

recommendations

recommendations,

resident.

were accepted for

and prescriber

Included

the category

acceptances of these

prescribers

implement drug

recommendations.

were those who

dose adjustment or

selected testing

drug regimen

based on their

change.

medical
decision.
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Blagec et al.,

Austria

To evaluate the

Survey B was a

Survey B

Scores on the

Out of a possible

2016

and

perception and

quantitative

included a final

usability,

max score of 16,

United

usability of a

assessment of

sample of 39

trustworthiness,

usability scored

States

web- and mobile-

physician and

physicians and

usefulness, and

an average of

enabled CDS

pharmacist attitudes

pharmacists,

workflow

10.6,

system (the

toward the MCS

with an

integration

trustworthiness a

Medication

system based on two

overwhelming

subscales and total

10.5, usefulness a

Safety Code

hypothetical use

majority from

scale score.

11.4, and

(MSC)) for

cases. Twenty-five

Austria or

workflow

pharmacogenetic

follow-up questions,

Germany

integration a 9.9.

s-guided drug

including a 16 item

(~90%).

This equates to a

therapy among

Likert scale, were

total scale score

physicians and

used to measure

of 42.3 out of

pharmacists.

usability,

64.There was no

trustworthiness,

statistically

usefulness, and

significant

workflow integration.

difference
between
physicians (43.7)
and pharmacists
(38.8), or
between
respondents
aware or unaware
of genome
guided
prescribing and
clinical decision
support systems.

Devine et al.,

United

To evaluate an

The study used a

Seven

Time to completion

Each physician

2014

States

early prototype,

convergent, parallel,

cardiology

of prescribing task.

spent between

commercial

mixed methods

fellows and

Themes and

3.6 to 4.9

CPOE

design. Physicians

three oncology

improvements

minutes per

system with

were given five

fellows at the

identified using the

prescribing task.

PGx-CDS alerts

hypothetical clinical

University of

heuristic evaluation

Nine themes and

in a simulated

case scenarios

Washington.

technique.

corresponding

environment, to

featuring a

improvements

identify potential

pharmacogenomic

emerged from the

improvements to

alert message

heuristic

the system user

triggered by a

evaluation. Five

interface, and to

medication order.

included

understand the

Audio-video

improvement

contexts under

recordings were

suggestions for

which PGx

coded according to

the CPOE user

knowledge

positive and negative

interface, two

embedded

evaluation heuristics.

suggested

39

in an electronic

including PGx

health record is

information

useful to

through alerts,

prescribers.

and three
emphasized the
need for relevant
guidelines and
dosing
recommendations
.

Dunbar et al.,

New

Feedback from

Once an appropriate

Forty-two

Key ways in which

Test results

2012

Zealand

clinicians on

patient was

clinicians

the test results were

utilization:

their experiences

identified, the

ordered the test

used and the

confirm a clinical

ordering a

clinician was directed

and a total of 33

perceived

decision, provide

AmpliChip®

to prescribe 'as

were

advantages and

reassurance,

CYP450 test kit,

usual', then complete

interviewed by

disadvantages of

provide

receiving results,

an order form for the

a member of the

using the test.

additional

utilization of the

patient to get the

research team.

information on

results, and

testing done. Results

Clinicians

patient response,

perceived

were fed back to the

worked across

influence the

advantages and

clinicians directly.

three District

dose of

disadvantage for

Ordering clinicians

Health Boards

risperidone, and

commencing

were contacted to

within New

doctor-patient.

treatment with

complete a

Zealand.

Several reasons

risperidone.

qualitative interview.

for not using
results were
delays in
receiving results,
inappropriate
setting (acute
unit with
requirement to
treat
immediately),
information
deemed
unnecessary, and
others Dose
determination,
reduction of
adverse effects,
and application
outside mental
health were noted
advantages.
Disadvantages

40

included results
being used at the
expense of
clinical
judgement, cost,
and practicalities
of the testing
process and
results reception.
Ferreri et al.

United

To determine the

Prospective

A single

Rate of prescriber

The majority of

2014

States

feasibility of

evaluation of the

pharmacy

acceptance to a

CPP

implementing a

program's feasibility

within a

Clinical Pharmacist

recommendations

PGx service in a

following a

regional chain

Practitioner (CPP)

were approved

community

retrospective data

known for

recommendation

by the prescriber.

pharmacy.

abstraction of

providing

across five different

There was 100%

prescription fills for

clinical

genotypes (*1/*1,

approval across

clopidogrel between

services.

*1/*2, *1/17,

genotypes *1/*1

the dates of May 1,

*17/*17, and

(EM), *17/*17

2011 and October 26,

*2/*17). The

(UM), and

2011.

number of patients

*2/*17 (IM).

with each were 9, 2,

Genotype *1/*2

4, 1, and 2,

(IM) was

respectively.

approved 50% of
the time, the
other 50% were
started on aspirin
EC 325 mg daily.
For genotype
*1/*17 (UM),
75% were
approved.
Clopidogrel was
discontinued in
the other patient.

Haga et al.,

United

To investigate

Two primary care

Twelve primary

Results from the

Five of nine

2017

States

provider

practices were

care providers

follow-up survey to

providers

utilization of

assessed, one with a

from two

assess perceptions

strongly or

pharmacist

pharmacist in the

internal

and comfort using

somewhat agreed

support in the

clinic and one with

medicine clinics

PGx. Patient charts

that felt more

delivery of PGx

available pharmacist

within the Duke

provided the

informed about

testing in a

on-call support.

University

number of PGx

PGx testing after

primary care

Physicians answered

Health System

tests ordered in

the trial. Six felt

setting.

a survey assessing

each arm of the

more

attitude, knowledge,

trial. Variables of

comfortable

and experience with

interest recorded by

discussing PGx

PGx testing before

the pharmacist

with patients

41

and after attending a

included the

after. Sixty-three

PGx seminar.

number of times a

total tests were

pharmacist was

ordered, 48 being

consulted (pre-test

ordered from the

or post-test), and

pharmacist-in-

how the results

house arm

were applied to

(p<0.00001).

treatment.

Physicians
consulted
pharmacists in 13
of the 15 cases in
the in-house
pharmacist group
compared to 7.5
out of 15 in the
on-call group.

Heale et al.,

United

To investigate

Mixed methods

A purposive

For information-

Average number

2017

States

physicians'

approach consisting

sample of six

seeking behavior in

of minutes spent

information

of a pre-study

physicians, five

the vignettes: time

in information-

needs and

questionnaire of

male and one

spent by physician

seeking session

information-

attitudes and

female. Three

on information-

was 8:22 (2:41 to

seeking behavior

knowledge regarding

were between

seeking, time

15:08), time

when exposed to

pharmacogenomics,

30 and 39 years

between

between

pharmacogenomi

observation of

old, two 40 to

navigational actions

navigation was

cs case vignettes.

information-seeking

49, and one 60

and number,

0:53 (0:03 to

in three case

to 69.

number of searches

8.27), number of

vignettes, and a post-

entered. Categories

page navigation

study questionnaire

of the information

events per

and interview.

needs from post-

subject per case

study assessment.

was 8 (1 to 18),
and the number
of searches was
2.3 (1 to 8).
Follow-up
assessment
identified six
information
needs categories
from 11 themes:
alternative
therapies
obviating testing,
guidance on
when and how to
test, frequency
testing is

42

indicated,
evidence of
importance of
genetic testing,
help in
understand
genetic effects,
and aid in
searching for
information.
Ielmini et al.,

Italy

2018

To identify if the

Observational study

Psychiatrist

Patients' overall

At baseline, 13%

treatment

with a follow-up at 3

decision

assessment and

of patients

prescribed by the

months. At baseline

making for 30

clinical evolution

received optimal

psychiatrist was

(T0), patients

bipolar type 1

was measured using

therapy. At

consistent with

received genetic tests

and 2 patients

the Clinical Global

follow-up, 40%

the treatment

and were given 4

who received

Impression. The

of patients

suggested by the

scales. At the follow-

PGT

Hamilton

changed to a

PGT at T0 and to

up (T0), changes to

Neurofarmagen

Depression Rating

therapy

assess if

treatment and

at 2 psychiatric

Scale assessed

consistent with

clinicians had

adverse events were

institutes

anxiety-depressive

the results of the

changed the

recorded.

symptoms. The

Nerofarmagen

treatment (in

Young Mania

test and 32%

case of

Rating Scale

maintained a

discordance) at

assessed manic

therapy

T1 (3-month

symptoms. The

disagreeing with

follow-up visit)

Dosage Record and

the test. A

according to the

Treatment

significant

results of the

Emergent Symptom

within-group

pharmacogenetic

Scale assessed onset

reduction in

test (PGT)

of side effects

adverse events

relating to ongoing

was observed in

pharmacological

patients who

therapy

received therapy
modification

Laerum et al.,
2013

Norway

Develop a

Algorithm applied to

Nine

Median time to

Scenario 1 took

prototype for

the interpretation of

experienced and

resolve the two

on average 164

automated

CYP3A5 and its

less-

scenarios presented

(110 to 339)

interpretation of

impact on the

experienced

and the speech and

seconds to

genetic tests and

metabolism of

physicians, five

actions recorded

complete. Most

evaluate hospital

immunosuppressive

of which

while using the

of the physicians

physicians’

drug tacrolimus.

completed

application.

were observed to

reactions to it in

Respondents used the

specialties after

Reactions to the

not immediately

a specific use

"think aloud"

qualifying as a

application after

grasp the concept

case.

technique to vocalize

Medical Doctor.

completing the

of "interpreted

thoughts and

One physician

scenario.

report" versus

43

considerations during

had a PhD in

original genetic

the application.

molecular

data. Scenario 2

Scenarios involved

genetics.

took less than

viewing and

half the time to

resolving two patient

resolve on

scenarios with regard

average than

to tacrolimus

scenario 1.

treatment. Physician

Physician

speech and actions

attitude to the

on the screen were

application was

recorded and they

generally very

were asked to

positive. Some

identify the correct

details were

dosing for the given

reported too

patient.

extensive,
unclear, or
difficult to
understand.

Lemke et al.,

United

To explore

Study participants

Fifteen primary

Broad themes and

The three broad

2017

States

primary care

received

care physicians

associated sub-

themes were

physicians’

complimentary PGx

in the

themes from the

perceived value

views of the

testing kits for

NorthShore

qualitative analysis

and utility of

utility and

themselves and for

University

were the primary

PGx testing,

delivery of direct

their patients. 30-

Health System,

outcome.

implementation

access to PGx

minute qualitative

a four-hospital

challenges, and

testing in a

semi-structured

community

provider and

community

interviews were

health system.

patient needs.

health system.

conducted to identify

The first theme

viewpoints related to

here included

primary care

two sub-themes:

physician PGx

how test findings

clinical decision-

can be used to

making.

guide primary
care decisionmaking, and how
information from
testing can lead
to specific
positive
outcomes for
patients.

Manzi et al,

United

To describe the

A retrospective

A total of 160

Percentage of

23% of

2017

States

development and

evaluation of the first

alerts across 31

prescribers who

prescribers

implementation

two years of

patients

cancelled the order

cancelled the

of a

operation (August

interfaced with

in response to alert,

order in response

comprehensive

2012 to August

69 unique

percentage who

to the TPMT

44

clinical

2014) of TPMT

practitioners.

initiated a modified

alert. 71% of

pharmacogenomi

single gene

53% physician,

dose after alert, and

prescribers

cs service within

sequencing and the

22%

percentage of tests

modified the

a pediatric

subsequent actions of

pharmacists,

order prior to initial

dose after

tertiary care

the clinician based on

18% nursing

prescription

receiving the

urban teaching

the CDS alert

with physician

alert for the

co-sign, and 7%

initial

nurse

prescription. 90%

practitioners

of tests were

hospital

ordered prior to
the drug being
ordered
McMichael et

Northern

To demonstrate

Psychiatrists were

Sixty-seven

Psychiatrists

Across the entire

al., 2017

Ireland

how attribute

given patient's pre or

practicing

estimated

sample, there

nonattendance

post treatment

psychiatrists

probability that they

was an 84%

analysis can be

symptom scores on

from Northern

will either ignore or

probability that

used in medical

the Positive and

Ireland

attend to

psychiatrists did

decision making

Negative Syndrome

recruited during

information about

not consider the

to assess whether

Scale (PANSS) for

continuous

the patient genotype

patient genotype

psychiatrists

two treatments of

professional

when already

information and

were influenced

schizophrenia, were

development

presented their

16% probability

in their treatment

told whether patients

meetings in

PANSS scores pre

they did when

recommendation

had a genotype

three hospitals.

and post.

already present

s by information

linked to one of the

with the patient’s

on the genotype

treatments associated

response to

of a patient,

with a 30% increase

treatment.

despite knowing

in effectiveness and

Psychiatrists with

the patient’s

were asked to

less than one

response to

recommend a

year of clinical

treatment.

treatment. Twenty-

experience were

six vignettes assessed

significantly

the effect of each

more likely to

attribute on

incorporate

psychiatrists'

irrelevant genetic

treatment

information into

recommendations.

patient treatment
(46%
probability).
Those with more
than 15 years had
a 7% probability
of incorporating
the same
information.
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Moaddeb et

United

To characterize

Pharmacists

Community

Length of the pre-

Over 80% of pre-

al., 2015

States

the experiences

completed surveys at

pharmacists in

test counseling, the

test counseling

and feasibility of

two time points for

North Carolina

medium in which

was under five

offering

each patient that was

across five

results were given

minutes, 84% of

pharmacogenetic

offered PGx testing.

community

to the patients and

results were

testing in a

One for when the

pharmacies.

how long that took,

communicated

community

testing was offered,

the pharmacist's

by phone,

pharmacy

and another after

belief of how well

pharmacists

setting. These

testing was

the patient

believed 95% of

included the time

completed and test

understood the

patients

to provide the

results were

results, and what

understood the

testing, patient

communicated.

percentage of result

results very well

interest,

Testing was offered

interpretations were

or somewhat

perceptions of

for CYP2C19 and/or

done correctly.

well, and

patients' post-test

SLCO1B1

pharmacist

comprehension,

interpretations

pharmacists'

were correct just

interactions with

under 90% of the

prescribing

time. Pharmacists

physician, and

reached out to a

changes made to

physician in 4

prescription

instances across

based on the

56 patients.

results.
Nishimura et

United

To determine if

A case scenario

Fifty-five

Physician response

40% of

al., 2016

States

physicians find

approach was use

physicians at

to the alert in an

physicians would

clinical decision

where the participant

the University

actual clinical

cancel and 49%

support alerts for

was responsible for

of Washington

interaction.

would modify

pharmacogenomi

prescribing dual anti-

enrolled in the

Usefulness of the

their initial order

c drug-gene

platelet therapy. The

study. 58% of

alert in general,

for aspirin or

interactions

participant was

these were

quality of the alert's

clopidogrel after

useful and assess

directed to select a

attending

visual design,

seeing the alert.

their perceptions

therapy and then

physicians.

appropriateness of

4% stated they

of usability

regardless of choice a

Respondents

the alert in a clinical

would override

aspects that

pharmacogenomic

worked in

workflow, and

the alert. 7%

impact

alert for clopidogrel

major medical

usefulness of the

reported "Other"

usefulness.

and the CYP2C19

centers,

pharmacogenomic

and responded

variant was shown.

outpatient and

content.

they would

This was followed by

specialty

contact a

a 15-item

clinics, and

pharmacist.

questionnaire and

emergency

Close to 90%

open-ended questions

departments.

agreed or

on their response to

strongly agreed

the alert.

the alert was
helpful, the text
was helpful for

46

decision making,
and that the alert
came at the
appropriate time.
30% of
physicians were
unsure that
pharmacogenomi
c data was useful
for their practice.
Nutescu et al.,

United

To determine the

Prospective,

The EHR

Adherence of the

A total of 353

2013

States

procedural

observational study.

system for the

medical staff to

dose

feasibility of a

Patients that received

University of

doses recommended

recommendations

pharmacist-led

genotype-guided

Illinois -

by the

were provided

interdisciplinary

warfarin therapy

Chicago.

pharmacogenetics

for the 80

service for

provided written,

Clinical dose

service. Acceptance

patients enrolled.

providing

informed consent for

recommendatio

of the dose

During the initial

genotype-guided

use of their data and

ns are made by

recommended

six months of the

warfarin dosing

leftover genetic

the

defined as within

service, 73% of

for hospitalized

sample. Recorded

pharmacogeneti

0.5 mg.

warfarin doses

patients newly

information included

cs consult team.

starting warfarin.

time of initial

primary team

genotype and consult

were within 0.5

order, time to results

mg of the

appearing in EHR,

recommended

time to initial consult

dose by the

and genotype guided

clinical

dose

pharmacist on the

recommendation,

pharmacogenetic

warfarin doses.

s service. There

ordered by the

was a noted
increase in
adherence to the
dose
recommendations
over time: 66%
in months one
and two, 76% in
months three and
fourth, and 80%
in months five
and six.
Overby et al.

United

Pilot study to

Clinical experts

Fifteen

Assessments of

Across both high

2015

States

assess the

helped develop

oncology and

clinical impact

and low

physician,

hypothetical clinical

seven

measured by

actionable alerts,

technology, and

case scenarios that

cardiology

prescribing uptake,

fellows used the

47

task

prompted prescribing

fellows

prescribing intent,

gene specific

characteristics of

tasks, and revisions

practicing at the

and change in

resources 88% of

effective

of scenarios that

University of

personalized drug

the time and the

communication

included presentation

Washington.

dosing (PDD).

alert message

and clinical

of PGx information.

evidence 74% of

impact of using a

Each participant was

the time. Sixty-

prototype CDS

presented with five

five percent of

system

scenarios. The third-

physicians

embedded in the

fifth were deployed

changed the

EHR to deliver

in a pseudo-

prescribed dose

PGx information.

randomized fashion.

after using the
PGx-CDS. A
significant
change
(decrease) was
only observed for
capecitabine and
mercaptopurine/t
hioguanine.

Payne et al.,

United

To compare the

A discrete choice

One hundred

The five attributes

Health-care

2011

Kingdom

preferences of

experiment through

thirty-eight

were level of

professionals

patients and

an online survey that

healthcare

information given,

were willing to

health-care

consisted of five,

professionals

predictive ability of

wait 2.2 days on

professionals for

four-level attributes

(83%

the test, how the

average for a 1%

the key attributes

resulting in 1024

physician) with

sample is collected,

improvement in

of a PGx testing

possible scenarios.

experience of

turnaround time for

predictive

service to

This was done

prescribing and

a result, who

accuracy. They

identify a

alongside a

advising on

explains the test

were willing to

patient’s risk of

prospective

azathioprine.

result.

wait 8.9 days for

developing a side

randomized

high levels of

effect

controlled trial

information

(neutropenia)

(TARGET study).

provision.

from the

Health-care

immunosuppress

professionals

ant, azathioprine.

preferred the
physician over
the pharmacist in
the delivery of
results. They
were willing to
wait 9.5 days and
give up 4.4% in
predictive ability
of the test. This
percentage
increased to 6.1

48

for the hospital
doctor to deliver
the result. No
significant
differences in
how the sample
is collected.
Peppercorn et

United

To assess the use

Anonymous cross-

Final survey

Response to

For a

al., 2013

States

of the CYP2D6

sectional survey that

was mailed to a

hypothetical test

premenopausal

test for

evaluated knowledge

random sample

results presented

woman with a

tamoxifen

of the CYP2D6 test,

of all breast

through three

poor metabolizer

metabolism

use outside of trials,

cancer medical

scenarios regarding

(PM) genotype,

outside of

requests by patients

oncologists

managing

33% would make

clinical trials and

and third parties, and

affiliated with

management of

no changes,

the attitudes of

a response to

the National

patients on

whereas 56%

community-

hypothetical test

Comprehensive

tamoxifen who

would change

based oncologists

results. Associations

Cancer

obtained

therapy. There

and breast cancer

between practice

Network

commercially

were significant

specialists about

setting and CYP2D6

(NCCNOs) and

available CYP2D6

differences

testing among

knowledge, use of

a random

results from an

between

patients with

the test for

sample of

external source

NCCNOs and

breast cancer

tamoxifen, and

community-

CBOs on what

eligible for

practice patterns

based

specific change

tamoxifen

were evaluated.

oncologists

would be made.

therapy.

Survey was piloted

(CBOs) from

66% of

with oncologists at

the American

respondents

the Duke University

Society of

made no change

Medical Center in

Clinical

when it was a

Durham, NC.

Oncology

premenopausal
woman with an
intermediate
genotype, 20%
would change.
The last case
involved a PM
postmenopausal
woman and only
14% of
respondents said
they would not
change therapy.

Peterson et al.,

United

Solicit clinician's

Online survey design

Clinicians at

Responses to the

For the

2016

States

perceptions of

with questions based

Vanderbilt

question of which

clopidogrel and

clinical utility,

on a previous

University

providers were

CYP2C19

preparedness to
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Hypothetical clinical case scenarios
Studies in this section are defined by their approach to engaging a provider in an exercise
that mimics real-world clinical decision making in some form. Of the nine studies included in
this section, there are three main sub-sections that can be defined. These three sub-sections are:
information seeking, prescribing tasks, and other. The first of these sub-sections, “information
seeking” includes three studies that aimed to directly measure the time it took to complete certain
tasks involving the use of pharmacogenomic information.23,26,41 All three qualitatively assessed
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reactions to the information-seeking process either during or after the exercise. In addition to the
time it took to complete the task, one study measured the number of searches and page
navigation events that took place as the provider attempted to answer their question.26 The
variability between the findings of each of the included studies was high given the inherent
differences among clinical decision support systems (CDS) and study tasks. One study used two
scenarios to gauge improvement in the time to complete from scenario 1 to scenario 2.41 These
studies cut across physician specialties, from internists to cardiologists and oncologists, and
included multiple disease states and/or pharmacogenes. The sample size was small for these
studies, ranging from 6 to 10 physicians. Due to variability in the tasks, it is difficult to make
comparisons between the studies. However, physicians spent between three and half to five
minutes on the prescribing task and upwards of eight minutes on information-seeking.
The second sub-section, “prescribing tasks”, included three studies wherein the
prescriber’s hypothetical actions taken when presented with pharmacogenomic information were
evaluated.29,31,32 Variables measured in these studies included the percentages of physicians who
would change a decision or initial orders based on new pharmacogenomic information, response
to or dismissal of CDS messages, as well as evaluations of whether the alerts or information
were helpful in decision making. All studies in this section were quantitative in methodology.
The sample size was larger for this sub-section, ranging from 15 to over 200 physicians. Overall
these providers agreed that the alerts were helpful and there was high utilization of the clinical
decision support resource. Changes in decision making based on this gene specific information
were noted in most of the cases.
The third sub-section, “other”, included three studies which each had unique
approaches.39,40,42 The first aimed to understand different objectives including an attitude
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assessment of a CDS tool usability, the second evaluated the use of irrelevant genomic
information by psychiatrists with differing experience levels, and lastly, a survey examined the
inter-country differences as drivers of oncologist test ordering. Like the previous section,
providers involved in the studies cut across specialties and quantitative outcomes were reported.
However, the sample in one study included both physicians and pharmacists. Attitudes toward
the CDS were moderately positive (42.3 out of 64), younger psychiatrists were significantly
more likely to use irrelevant genomic information than their colleagues with more than 15 years’
experience, and US oncologists opted for testing more than their German counterparts.
Prospective or retrospective real-world studies of prescribing/testing decisions
This section includes seven of the 25 studies, five of which were prospectively designed
and two that used a retrospective chart review methodology. This can be further broken down
into two sub-sections: first, studies that explicitly stated the prescribers action being based on the
recommendation of a pharmacist or pharmacist-led surveillance service,22,24,30,34 and secondly,
those studies that either prospectively or retrospectively evaluated prescriber decision making
based on a CDS alert37,38 or another form of communication, the type of which was not explicitly
stated.46
Among the four studies in the first sub-section, those where clinical recommendations
either came directly from a pharmacist or from a pharmacist led pharmacogenomic service, the
primary aim was to ascertain the frequency with which prescribers accepted these
recommendations and for what types of patients (i.e., metabolizer status) did this occur.
Prescriber response to the pharmacist recommendation was separated by the metabolizer status
of the patient in two of the studies.24,34 Two studies30,46 also incorporated an evaluation of the
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prescriber response over time and most study outcomes were based on at least six months of
data. Study size ranged widely from actions taken on 18 patients up to decisions on 514. Two
studies focused on genotype-tailored antiplatelet therapy, one on the dosing of warfarin, one
focused on psychiatric medications, and one that cut across therapeutic areas. Acceptance of
pharmacist recommendations overall was high, however lower rates can be seen when the
recommendation from the pharmacist was to make a therapeutic modification.
In the second sub-section the outcome of interest was not adherence to a pharmacist
recommendation, rather it was adherence to an internal CDS system or interpreted results and
guidance from the testing lab/company. Two of the three studies in this sub-section produced
outcomes from a retrospective chart review to evaluate adherence to testing.37,38 Interestingly,
both studies share additional similarities including a sole focus on TPMT testing and the use of a
“pretest CDS alert”. This means that the CDS system, rather than guiding the provider on
prescribing, informed them that testing is indicated prior to any initial dosing. Pre-test alerts
resulted in about 25% of recommended tests being ordered in one study and 90% in another.
High rates of modification in doses occurred when prescribers received an alert after the initial
prescription.
Cross-sectional quantitative surveys
The cross-sectional quantitative survey section includes five studies that employ unique
methodologies to measure response from providers involved in pharmacogenomics.28,33,35,43,44
Given the uniqueness of each study, no sub-sections were developed here.
One study was based on an actual implementation project across a series of community
pharmacies.28 This study captured a holistic perspective from pharmacists not only on their
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experiences with delivering pharmacogenomics but also their perceptions of the patients’
experiences as well.28 The survey of interest was offered after the testing of CYP2C19 and
SLCO1B1 was complete and test results communicated.28 A discrete choice experiment was
conducted along a randomized controlled trial involving use of azathioprine.43 This study
examined the trade-offs healthcare professionals were willing to make across numerous variables
including predictive ability of the test, wait time for results, and information provision.43 The
third study in this section evaluated physician (both psychiatrists and general practitioners)
attitudes toward pharmacogenomic testing for antidepressant and antipsychotic medications at
the time of a patient follow-up visit, 6-8 weeks after test results were received.44
The last two studies were conducted in two large-scale academic implementation
programs for pharmacogenomics: Mayo Clinic and Vanderbilt University Medical Center
(VUMC).33,35 The study from the Mayo Clinic’s RIGHT protocol assessed the positive or
negative aspects of a pharmacogenomic alert.35 This study also included data similar to the last
section that tracked the type and number of alerts that subsequently resulted in a prescription
change.35 The VUMC study aimed to uncover perceptions of both cardiology and non-cardiology
providers about who should be notified of the pharmacogenomic results and who should be
primarily responsible for managing the patient.33
The latter four studies had between 80 and 159 physician respondents while the former
never explicitly stated the number of pharmacists responding to the survey.33,35,43,44 Rather, the
reader is informed of the number of participating pharmacies (n=5) and the number of patients
engaged by these pharmacists (n=69). The results of the DCE study revealed several interesting
tradeoffs physicians were willing to make for higher levels of information and predictive ability
of the test.43 There was rather strong agreement among cardiology and non-cardiology providers
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regarding returning results to both the specialist treating and the original prescriber of the drug
therapy, as well as agreement that the specialist should be responsible for acting on the result. 33
Cross-sectional qualitative survey methods
Qualitative survey methodology uses less structured methodologies such as interviews,
focus groups, or open-ended surveys. The use of in-depth interviews was the unanimous choice
among researchers for studies included in this group.27,36,45 One focused on mental health
providers and elicited specific reasons for and against utilizing test results as well as the
advantages and disadvantages of testing more generally.45 This study contrasts to the other two
in that a thematic analysis was not the intent of the findings. A second study targeted primary
care physicians to understand more deeply the value and utility of pharmacogenomics, as well as
its use to guide clinical decision-making.27 Participants here were also given complimentary
testing kits for themselves and their patients. The last study included both primary care and
cardiology providers and utilized a thematic approach in the analysis.36
The number of interviews conducted range from 15 to 33 individuals across the studies.
The nature of the qualitative methodology seemed to lend itself to a broader assessment of
provider involvement with pharmacogenomics, rather than a narrow focus on a specific druggene pair. Results of particular interest include the noted advantages of results for decision
confirmation and reassurance, however there were perceived disadvantages including the use
genomic results at the expense of clinical judgment and worries of handoffs to providers outside
established implementation programs.36,45
Quasi-experimental
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Quasi-experimental studies involve manipulating one or more variables, but without the
random assignment of participants to one condition or the other. Only one study included in our
search fit this criteria and thus was given its own section.25 Framing the study as a pilot, the
authors designed a two-armed (physician vs. pharmacist-initiated testing) intervention trial with
pre-post survey assessments of the primary care physicians involved in each arm. The survey
results were supplemented by chart reviews of the 6-month follow-up period from the beginning
of the trial. Six different tests (CYP2D6, -2C19, -2C9, VKORCI, HLA-B*1502, and SLCOB1)
were offered and made available for ordering during the trial. Results from this study found that
significantly higher levels test were ordered from the pharmacist in-house arm (48 of 63 total
tests ordered) and physicians consulted pharmacists at nearly twice the rate in the in-house arm.

60

4. DISCUSSION
This scoping review examined the characteristics of 25 peer-reviewed studies, published
since the year 2000 and concentrated on illuminating the prevailing methodologies used to
examine the active use of pharmacogenomics (PGx) in practice. The decision to identify
methodologies used in implementing PGx in practice was a reaction to the saturation of the
literature with cross-sectional health care professional awareness and attitude studies. A common
thread in these awareness and attitude studies is that health care professionals find
pharmacogenomics useful to patient care, but in most cases lack the requisite knowledge to
deliver it effectively.8,15,16,47,48 While valuable, especially in the early stages of implementing a
health innovation, these types of studies tend to lack elements that should be considered for
sustainability, as outlined in the DSF.19
Our content analysis of the study designs and methods identified five unique groupings that
researchers had employed during the time frame of the search. This included hypothetical
clinical case scenarios, real-world studies on prescribing/testing decisions, cross-sectional
quantitative surveys, cross-sectional qualitative interviews, and quasi-experimental studies.
Separating the studies into five-year blocks, a trend of an increasing number of studies fitting our
inclusion criteria can be seen, with nearly 70% published in the last four years. Most of these
studies produced quantitative outcomes and were conducted by researchers in the United States.
Interestingly, our review did not include any studies where the genetic counselor was the health
care professional involved in using pharmacogenomic information.
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The included studies demonstrate a continued focus on decision making within the
confines of the EHR. Most studies of this nature came from the hypothetical case-based
scenarios designed to mimic real-world practice. These types of studies fit well at the
intersection of the three genomic sustainability constructs outlined at the beginning of this
review: clinician education, CDS tools, and workflow integration.10 The importance of welldesigned CDS has been a central focus among leading implementation programs for
pharmacogenomics. Research from groups such as the Clinical Pharmacogenetics
Implementation Consortium’s (CPIC) Informatics Working Group provides suggestions best
practices for integrating CDS with pharmacogenomics for clinical delivery.49 Other leaders in the
field point to the importance and challenge of developing standardized representations of results
and identifying the right person to receive a CDS alert.50,51 The feasibility of many of the studies
included in this section is driven by the translation of pharmacogenomic information into a
discrete data field that can be called upon when applicable. EHRs without this functionality
make it impossible for prescribers to use this information efficiently.52 Given the variability
between studies, future research on prescriber interactions with a with pharmacogenomic CDS
should pursue comparative and longitudinal study designs to elucidate the most effective way to
deliver this information.
Additional findings from the review indicate that there has been a concerted effort from
several ongoing implementation programs to understand who should be acting on
pharmacogenomic information and how well these providers perform. These types of studies are
crucially important as they provide the real-world program with a sense of “buy-in” from
prescribers. This was typically achieved in one of three ways: by measuring adherence or
compliance to a pharmacist- or CDS-based dosing recommendation, measuring engagement with
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the platform and any medication changes without the recommendation aspect, or measuring
ordering rates based on a pre-test alert to inform the prescriber that a test prior to any dosing is
indicated. Following providers over time to see how their adherence behavior changes should be
considered for studies in the future. A single cross-sectional assessment would likely miss this
trend if applied in other settings. Clinician’s limited exposure to pharmacogenomics has been
previously noted in the literature.7,15,47 This unfamiliarity with using the information may
contribute to a hesitancy to adopt these suggestions immediately. Supplementing these types of
studies with qualitative assessments of why adherence to recommendations was higher or lower
would strengthen these studies and help the discipline identify areas to intervene and make
improvements.
There will be a continued need to communicate the value and validity of pharmacist or CDS
based recommendations more broadly. Pharmacist leadership and involvement with crafting the
delivery of pharmacogenomics in clinical care has been strong to date and continuing this trend
should be maintained for new practice settings when feasible.5,12,13,53 The infrastructure of the
individual institution or practice will most likely guide whether clinical decision support or
pharmacist guided recommendation is most appropriate for delivering clinical
pharmacogenomics.
Outside of the formal implementation program, the feasibility of delivering
pharmacogenomics through the pharmacist and a community pharmacy setting is an ongoing
stream of research for the pharmacogenomics community.17,54,55 Two studies herein illuminate
some of the operational considerations such as the time needed for a pharmacogenomic consult,
perceived patient understanding, and the ability of the pharmacist to interpret this information
correctly.25,28 Both studies were conducted by the same group of researchers and in the same
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state, thus the broader generalizability of the findings may be limited. However, these are
excellent models for future researchers to mimic and establish broader validity. Pharmacist
engagement in pharmacogenomics has support from their largest professional organizations, the
American Society for Health-System Pharmacists and the American Pharmacists
Associations.56,57 Collaborative models of care with physicians, such as formal collaborative
practice agreements, is likely the more sustainable path as consistent reimbursement for clinical
pharmacy services remains elusive.58 Furthermore, the integration of the genetic counselor into
the physician-pharmacist collaboration would enhance the comprehensiveness of the patient
experience and should be experimentally explored in the future.
The findings from our scoping review reveal a plethora of study designs, types of providers
involved, and drug-gene pairs serving as the clinical scenario for consideration. Almost all
studies from the scoping review included a physician sample, with only one study exclusively
focusing on pharmacists. However, several physician specialties (oncology, cardiology,
psychiatry, endocrinology, internal and family medicine) were included. While most decision
making and prescribing is done by physicians, future research should aim to do the same
regarding the pharmacist’s actual experiences with using and acting on pharmacogenomic
information. This will help achieve one of the research directions of Volpi et al., to study the
pharmacist as the “clinical champion” for pharmacogenomics.5
The results of this review are not without limitations. First, the timeframe excluded
studies published after 2018 and thus likely missed some of the most recent studies. Given the
fact that 70% of the included studies were in the last four years, this is highly likely. Many of the
studies herein were published from some of the most mature pharmacogenomic implementation
programs in the world. The inclusion of many of these studies is likely due to the nature of our
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research question and inclusion requirements. More work should be done to explore these same
ideas in community practice. The nature of a scoping review does not allow for the synthesis of
results across studies and thus this was not our aim. However, the hope is that this review will
provide the research community with a keener eye for trends and specific research questions that
may lend themselves to such an exploration.
In summary, this scoping review provides the pharmacogenomic research community
with a compilation of the studies from the turn of the century that have aimed to collect data on
the experiences or actions of health care professionals engaged in using pharmacogenomic
information. We further focused the review on the methodologies employed by the authors and
broke this down into five separate categories. The interactions of providers with clinical decision
support systems and adherence to therapeutic recommendations represented many of the
included studies. A broad thematic analysis of the methods and findings provided structure to a
discussion that will hopefully guide further research on those factors needed for successful
integration of pharmacogenomics into clinical care.
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APPENDIX 1. Search Strategy

MEDLINE® MeSH® search string was as follows:
(((((((("Pharmacogenetics"[Mesh]) AND "Health Personnel"[Mesh])) OR
(("Pharmacogenetics"[Mesh]) AND "Attitude of Health Personnel"[Mesh])) OR
(("Pharmacogenetics"[Mesh]) AND "Genetic Counseling"[Mesh])) OR
(("Pharmacogenetics"[Mesh]) AND "Education"[Mesh])) OR (("Pharmacogenetics"[Mesh])
AND "Surveys and Questionnaires"[Mesh])) OR (("Pharmacogenetics"[Mesh]) AND
"Physicians"[Mesh])) OR (("Pharmacogenetics"[Mesh]) AND "Pharmacists"[Mesh]).

Embase® Emtree® search string was as follows:
('pharmacogenetics'/exp AND 'health care personnel'/exp AND [embase]/lim OR
('pharmacogenetics'/exp AND 'health personnel attitude'/exp AND [embase]/lim) OR
('pharmacogenetics'/exp AND 'physician'/exp AND [embase]/lim) OR ('pharmacogenetics'/exp
AND 'pharmacist'/exp AND [embase]/lim) OR ('pharmacogenetics'/exp AND 'genetic
counseling'/exp AND [embase]/lim) OR ('pharmacogenetics'/exp AND 'education'/exp AND
[embase]/lim) OR ('pharmacogenetics'/exp AND 'questionnaire'/exp AND [embase]/lim)) AND
([article]/lim OR [article in press]/lim OR [short survey]/lim) AND [english]/lim AND
[embase]/lim AND [2000-2019]/py.

72

APPENDIX 2. - STROBE Statement—Checklist of items that should be included
in reports of observational studies

Item
number

Recommendation

(a) Indicate the study’s design with a commonly used term in the title or
the abstract
Title and Abstract

1
(b) Provide in the abstract an informative and balanced summary of what
was done and what was found

Introduction
Background/rationale

2

Explain the scientific background and rationale for the investigation
being reported

Objectives

3

State specific objectives, including any prespecified hypotheses

Study design

4

Present key elements of study design early in the paper

Setting

5

Describe the setting, locations, and relevant dates, including periods of
recruitment, exposure, follow-up, and data collection

Methods

(a) Cohort study—Give the eligibility criteria, and the sources and
methods of selection of participants. Describe methods of follow-up

Participants

6

Case-control study—Give the eligibility criteria, and the sources and
methods of case ascertainment and control selection. Give the rationale
for the choice of cases and controls

Cross-sectional study—Give the eligibility criteria, and the sources and
methods of selection of participants
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(b) Cohort study—For matched studies, give matching criteria and
number of exposed and unexposed

Case-control study—For matched studies, give matching criteria and the
number of controls per case
Variables

Data sources/
measurement

7

Clearly define all outcomes, exposures, predictors, potential confounders,
and effect modifiers. Give diagnostic criteria, if applicable

8*

For each variable of interest, give sources of data and details of methods
of assessment (measurement). Describe comparability of assessment
methods if there is more than one group

9

Describe any efforts to address potential sources of bias

10

Explain how the study size was arrived at

11

Explain how quantitative variables were handled in the analyses. If
applicable, describe which groupings were chosen and why

Bias
(NOT USED)
Study size
Quantitative variables
(NOT USED)

(a) Describe all statistical methods, including those used to control for
confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up was
addressed

Statistical methods
12
(NOT USED)

Case-control study—If applicable, explain how matching of cases and
controls was addressed
Cross-sectional study—If applicable, describe analytical methods taking
account of sampling strategy
(e) Describe any sensitivity analyses
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SECTION II.
SUSTAINABLE ADVANCEMENT OF EARLY ADOPTER SUCCESS IN
HEALTH SYSTEM PHARMACOGENOMICS: STRATEGIES AND
PERSPECTIVES FROM IMPLEMENTATION LEADERSHIP
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1. BACKGROUND
From 2012 to 2016, only 1.75% of genomics-related grants included the formal use of an
implementation science framework.1 This equates to a total of four grants, all of which used the
same framework, Everett Roger’s Diffusion of Innovation.2 The Center for Disease Control and
Prevention’s (CDC’s) Public Health Genomics Knowledge Base identified 283 articles published
in 2014 where implementation science has been applied to genomic medicine.3 However, the
inclusion criteria did not specify that a formal implementation science approach must be taken,
rather that the studies “contributed to our understanding of the implementation of genetic/-omic
testing…”.3 In fact, what was discovered was that very few studies actually incorporated a
theoretical framework from implementation science.3
In late 2018 the CDC Office of Public Health Genomics blog made an urgent call for the
integration of implementation science in genomic medicine. They highlight that although an
evidence base is critical, we must also understand “what factors contribute to the success or
failure of a genomic application within a particular setting”.4 A recent “priority-setting” study
identified 28 constructs of importance for genomic medicine sustainability.5 Several of the topranked constructs have direct implications for the clinical delivery of pharmacogenomics: a need
for expanded genomic education, addressing a lack of available genomic-focused clinical
decision support (CDS) tools, and improving the integration of genomic information into clinical
workflow. In fact, the sixth-ranked construct important for genomic medicine sustainability was
the expansion of implementation science research.5
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Evidence supporting the top rankings of these constructs include many previous studies
that focus on the need for robust provider knowledge and seamless integration of information
into the workflow. These issues have been consistently recognized as part of best-practice when
implementing pharmacogenomics, a leading example of genomic medicine and the science of
identifying genetic variants that may influence the safety or effectiveness of a drug in a patient.6-8
However, as mature and advanced programs still face challenges in this area, it is not difficult to
imagine that more pharmacogenomic-naïve health care settings will struggle with these
insufficiencies even more.9-15 Formal training for providers in pharmacogenomics has been
reported as low as 11% for physicians, and 17% for pharmacists.9,10,14 More recent work has
qualitatively explored the ongoing physician needs and suggestions for improvement regarding
pharmacogenomic clinical decision support (CDS).15 The nuances of which will require
thoughtful design to achieve the seamless integration with current clinical workflows. On a
positive note there is consistency throughout the literature that both physicians and pharmacists
have favorable attitudes toward the use pharmacogenomics in patient care, but the confidence to
use these results appropriately remains an issue.9,11,16-18
Leaders in the implementation of pharmacogenomics recently put forth some ‘lessons
learned’ and ‘research directions’ needed for the field, including several aligned with these
sustainability indicators.19,20 Two particularly applicable ‘lessons learned’ for clinical
implementation of pharmacogenomics are the importance of “stakeholder alignment and
transdisciplinary teams” and the need for a “standardization of local factors (e.g. population,
clinician workflow, and resources)”.19 Transdisciplinary teams have been driving
pharmacogenomic implementation thus far, with both senior pharmacist and physician providers
acting as successful program leads.21-25 Advancing health system pharmacogenomics will be
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improved by identifying an appropriate, local ‘clinical champion’ and aligning transdisciplinary
stakeholders based on the resources of the that context.19 Echoing the tone of the CDC, the
application of implementation science can operationalize the ‘standardization of local factors’ by
the “collection of data on dissemination and implementation from early sites of adoption using
validated frameworks”.19 Despite sparse use of validated frameworks to date, a relationship
between implementation science and genomic medicine has continued to develop.3,5,26-30
Applying an implementation science methodology is essential for advancing pharmacogenomics
in local health system contexts, many of which will have fewer resources than previous
implementation programs.
The current need from the pharmacogenomic research community is to answer the call
for more integration of implementation science into genomic medicine from the CDC and
leading clinical implementers. As such, our objective is to provide a qualitative assessment of
perspectives and potential strategies for clinical pharmacogenomic implementation from a
sample of early adopter leadership in the field. To accomplish this goal and to pursue a focus on
the constructs needed for the sustainability of genomic medicine, we have applied the
Consolidated Framework for Implementation Science (CFIR)31. The CFIR is comprised of 39
constructs across five domains and is described by its developers as a “meta-theoretical”
framework that can guide an understanding of where and why an intervention works.31 With the
application of a validated framework, we aim to move the field toward a more robust
understanding of local factors to enable success in additional settings.19
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2. METHODS
Study design
Semi-structured, in-depth interviews were used as the specific methodology for this
study. In-depth interviews have been suggested for use in the examination of the CFIR
‘reflecting and evaluating’ (Process domain) constructs.29 They are also critical to uncovering
insights for the translation and dissemination of an intervention in resource constrained
environments, such as health care.29,32 The study was approved by the University of Mississippi
institutional review board (Protocol #19x-206).
Study population and sampling strategy
Leaders involved at sites that have implemented pharmacogenomics were targeted for
interviews using a purposive sampling design. Inclusion criteria include professional credentials
of a physician (MD or DO), pharmacist (PharmD or RPh), or a clinical research scientist (PhD),
and current or previous leadership involvement in an active pharmacogenomic implementation
project. An initial list of potential respondents was brainstormed among two authors (NK and
JH) according to one author’s (JH) experience as a member of the pharmacogenomic leadership
team at their home institution. Individuals from 18 unique organizations were initially identified,
with some organizations having two potential respondents. In instances where two individuals
from one institution were identified, authors ensured that these respondents had differing
professional credentials (i.e. MD and PharmD) and played differing roles in the implementation
of pharmacogenomic programs.
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Interview guide development
An adapted version of the CFIR semi-structured interview guide, focusing specifically on
the Process domain (cfirguide.org), was deployed in this study and is available in Appendix 1.33
The Process domain is made up of the four constructs: planning, engaging, executing, plus
reflecting and evaluating. The engaging construct is then further broken down into six subconstructs: formally appointed implementation leaders, opinion leaders, champions, key
stakeholders, innovation participants, and external change agents.31 The Process domain was
chosen for two reasons. First, its constructs, and sub-constructs best fit the study objective and
ultimate intention to improve the long-term sustainability of genomic medicine. Secondly, the
IGNITE Common Measures Working Group (CMG) recently evaluated the CFIR for its
potential contribution to genomic medicine and included three of the Process domain constructs
(engaging, executing, and reflecting & evaluating) in its list of highest priority CFIR constructs
for genomic medicine implementation.29 Table 1 shows each construct, sub-construct, and
corresponding definitions provided in the CFIR Codebook.31
The constructs and sub-constructs of the CFIR Process domain are described as the
“essential activities of the implementation process…[that] can be accomplished formally or
informally…in any order…[and] can be revisited, expanded, refined, and re-evaluated.”31 The
domain is linearly designed starting from the Planning construct through Engaging and
Executing and finishing at the Reflecting & Evaluating constructs, yet the framework authors
realize a real-world implementation will not always move this way. For example, new planning
activities may be necessary as ideas come to light during other execution phases.
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The CFIR guide was written using present, future, and past tense at different points. For
our purposes, some of the included questions were edited to focus on a retrospective evaluation
since many programs were implemented several years ago. For example, in the Reflecting &
Evaluating domain, the question “Will feedback be elicited from staff? From individuals served
by your organization?” was replaced with “Have you collected structured feedback from clinical
staff on their experiences with pharmacogenomics?”. The initial guide was drafted by NK,
reviewed and edited by MR and JH, and approved by all authors before use. The interview guide
was pre-tested in a question – response – feedback format with a clinical implementer of
pharmacogenomics whose responses were then ineligible for analysis. Several questions were
removed following this pre-test because the questions were deemed either irrelevant or
potentially confusing to respondents.
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Table 1. Process domain construct and sub-construct definitions
Construct
Definition
The degree to which a scheme or method of behavior and
Planning
tasks for implementing an intervention are developed in
advance and the quality of the schemes or methods
Attracting and involving appropriate individuals in the
implementation and use of the intervention through a
combined strategy of social marketing, education, role
modeling, training, and other similar activities

Engaging

Individuals from within the organization who have been formally
Formally appointed
appointed with responsibility for implementing an intervention as
implementation leaders
coordinator, project manager, team leader, or other similar role
Individuals in an organization who have formal or informal
Opinion leaders influence on the attitudes and beliefs of their colleagues with
respect to implementing the intervention
Individuals who dedicate themselves to supporting, marketing, and
Champions driving through an implementation, overcoming indifference or
resistance that the innovation may provoke in an organization
Individuals from within the organization that are directly impacted
Key stakeholders by the innovation, e.g., staff responsible for making referrals to a
new program or using a new work process
Innovation participants

Individuals served by the organization that participate in the
innovation, e.g., patients in a prevention program in a hospital

Individuals from within the organization that are directly impacted
External change agents by the innovation, e.g., staff responsible for making referrals to a
new program or using a new work process

Executing

Carrying out or accomplishing the implementation according
to plan

Reflecting & Evaluating

Quantitative and qualitative feedback about the progress and
quality of implementation accompanied with regular
personal and team debriefing about progress and experience

Data collection
Once the sample of potential participants was finalized, individuals were invited via
email and provided with a link to a demographic survey (Qualtrics, Provo, Utah) and scheduling
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poll (Doodle, Zurich, CH) (Appendices 2 and 3). A second “reminder” invitation was sent out
one week after the first if there is no response. These individuals were then contacted and
successfully interviewed. No incentive was offered.
Data analysis
Analysis of the final transcripts utilized resources and methodology from the CFIR
website (cfirguide.org).34 The CFIR codebook provides a definition of each construct and subconstruct as well as inclusion and exclusion criteria for respondent statements. The definitions
provided in the codebook were used to place verbatim quotes in the appropriate construct or subconstruct. Since the question guide was based on the CFIR Process domain, most often the data
were coded in the same construct as the corresponding question. However, at times, the elicited
response was better coded in another construct. The constant comparative approach was used to
compare each new transcript with one another to inductively identify thematic material within
the constructs and sub-constructs.32 Authors NK and JH read each transcript in full twice. A third
read through of the transcripts was done to identify which individual quotes best represented the
thematic material. No disagreements occurred that required the mediation by a third author.
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3. RESULTS
Twenty individuals were initially contacted to participate in the interviews. Two of these
individuals were unable to participate but recommended a colleague from their institution that
they felt fit the inclusion criteria. Seventeen individuals completed both the screener survey and
the subsequent in-depth interview. The remaining three individuals were not interviewed because
data saturation had already been achieved. Figure 1 presents the results of the demographic
survey. A little over half of the respondents were pharmacists (PharmD or RPh), while the
remaining participants were either physicians or clinical research scientists. Most participants
were CPIC members and came from academic institutions and/or institutions with at least three
years of pharmacogenomic implementation experience. The institutions represent by the
interview subjects mostly engage in single-gene and panel genotyping, as compared to
sequencing, and just under half have implemented a preemptive model of testing.
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Figure 1. Interviewed individuals’ demographics. PGx, pharmacogenomics; CPIC, Clinical Pharmacogenetic
Implementation Consortium; IGNITE, Implementing Genomics Into Practice; eMERGE, Electronic Medical
Records and Genomics; PGRN, Pharmacogenomics Research Network; PharmVar, Pharmacogene Variation
Consortium. Some participants may hold more than one professional credential (MD/DO, PharmD/RPh, and PhD).

Content Analysis
In the following sections interview participant responses to each of the constructs of the
Process domain will be outlined. These findings from the CFIR Process domain should be read
as an anecdotal guide for future managers of similar implementation programs. A summary of
the key themes can be found in Table 2.
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Table 2. Summary of key themes from constructs and sub-constructs of the CFIR Process
domain
CFIR Construct
Key Themes
•
•

Planning

Engaging

Subconstructs

Executing

Reflecting &
Evaluating

Define leadership and engagement with physicians
Determine where pharmacogenomics is already used and clinician
workflow needs
• Smart small and get and early win
• Formal vs. informal oversight structure
• Multi-disciplinary approach
Formally appointed internal
• Dedicated information
implementation leaders
technology (IT) full-time
equivalents (FTEs)
• Support from top leadership or
Opinion leaders
visionary clinician
• Cultural/organizational change
• Different champions for different
Champions
clinical services
• Informal, high-touch approach
• Utilizing pharmacists for
Key stakeholders
knowledge and communication
• Lack of formal education
• The patient case
• Engagement through the patient
Innovation participants
portal
• Patient referral
• CPIC
External change agents
• Peer organizations with similar
EHR systems
•
•
•

Lack of dedicated FTEs for pharmacogenomics
Feedback and adjustments to the clinical workflow
Creating a culture of resilience

•

Prevailing goals for many was simply to get the program up and
running
Process metrics (alerts fired, tests ordered, adherence to alerts)
prioritized over outcome studies

•

Planning construct
One of the key themes in the Planning construct was the need to have defined leadership
and engagement with physicians early on. As one scientist participant said, “Administrative
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support is definitely something that was instrumental. The hospital administration gave the
financial support and said, ‘You have a year, here’s some money to get started. Then it needs to
sustain itself.’” (Scientist)
Another important finding was the need to understand where pharmacogenomics was
being used and optimizing workflow. A pharmacist participant said, “Over the past year, we’ve
spent the majority of the time trying to determine where pharmacogenomics is already being
used in practice and focusing on optimizing the processes that are being employed.”
Understanding this will likely enable implementers to lock in one of our key themes of getting an
“early win”: One of the biggest pitfalls that early programs in pharmacogenomics can do is
oversell themselves. You're doing something novel. You need to have that win early on, so that
people know that you can get something done.” (Pharmacist)
There are mixed signals about what type of oversight structure is most appropriate and
how this should evolve. More specifically, one respondent said, “When we started, we very
quickly got a formal [committee] structure into P&T. That committee lasted about two years.
Then, the personalized medicine [group] kind of took over as the oversight”.(Pharmacist) Some
participants noted informal processes that have seemingly worked well, while others have
struggled without formal oversight in place. A pharmacist participant shared this, “Hopefully we
will have one [oversight committee] in the near future…because there's no formal group right
now…for the new drug-gene pair I'm trying to implement I think I have six different committees I
have to present in front of.”
Engaging construct
The Engaging construct is the only one that contains specifically identified subconstructs. The major thematic points in each sub-construct will be discussed in turn.
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Formally appointed internal implementation leaders
Since many of the participants were themselves the “formally appointed internal
implementation leader”, the interview guide questions were focused on high-level support
broadly and where interview participants said they wished more support would come from. At
more advanced institutions, formal leadership for genomic medicine has become engrained in the
culture. A physician participant stated, “It goes without saying that the administration has to
understand what it is we’re doing…but genomics implementation has been represented on the
clinical strategic plan for years. So, we've gone through a cultural shift about how to use
genomic information, so we don't have to go to administration to make a sell.” (Physician)
IT professionals were also frequently mentioned as being a crucial component to
implementation leadership. However, according to participants there were not enough of them.
In particular, a pharmacist said, “Essentially all of our precision medicine initiatives are based
on trying to use the EHR to its best effect. [This] could be farther along if we had more support
for those people. [Those] in charge of the EHRs are overwhelmed with work, overwhelmed with
emergencies, overwhelmed with fixing problems rather than working on strategic solutions.”
(Pharmacist)
Opinion Leaders
Several participants noted that institutional leadership and often a visionary clinician
with widespread respect was instrumental in the uptake of pharmacogenomics at their institution.
As one participant put it, “Having institutional leadership from people like deans, CEOs, and
whatnot, was incredibly helpful. For specific drug-gene interactions, I think having buy in of
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either the division chief or other clinical champions in that area has been really helpful.”
(Physician)
Beyond specific individuals, a “systems” mindset was advocated for by one participant
that reflected a broader finding that influence is better achieved with a cultural shift by saying,
“Well, I don't think it's one individual. I think you really must think broadly. I'm a systems
person, you're still going to have to have the systems in place that are really going to support
being able to implement effectively.” (Physician) Several participants, also noted the integral
role and leadership of pharmacists in the implementation of pharmacogenomics. One participant
explicitly noted the level of influence pharmacists have at their institution:
“Our physicians tend to trust the opinions of our pharmacists about how to manage
drug therapy. So, if the pharmacists hadn’t been on board, the physician probably
wouldn’t have gone for it. The pharmacists are really the ones who make a lot of
detailed decisions on how to adjust drug therapy, so if they hadn’t been on board, we
wouldn’t have been able to do the implementation” (Pharmacist)
Champions
The major theme herein was that engagement with a clinical champion is needed on both
an institutional level, and an individual service level. One participant said, “I think in any clinic
that you want to use a pharmacogenetic test, there needs to be a clinician champion there. It
takes clinician buy-in and not just somebody saying ‘Oh, we have a pharmacogenetic test here
we are implementing, and you can use it.” (Scientist) These physician champions were also
useful in promoting pharmacogenomics beyond their own service as one participant described,
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“Several of our docs come to mind right away because they’ve been champions outside of their
own division.” (Pharmacist)
Key Stakeholders
This sub-construct elicited one of the longest discussions in the interview. An informal,
high-touch approach to communication was consistently described by participants as successful
and in their opinion the best approach to engagement of key stakeholders. A Physician
participant stated, “We basically use more of a carpet-bombing approach…so we present it at
department meetings, we present it through CME, there are online opportunities where we can
present this type of information.” (Physician). A clinical pharmacist embedded with a physician
was seen by several participants as a “catalyst” for encouraging use. A pharmacist leader said, “I
utilized our clinical pharmacist first to really learn about the services, the clinicians, and try to
build upon the relationship that was already established with the pharmacy department in those
areas … I was able to be connected by someone that they already knew and trusted.”
(Pharmacist)
Few participants acknowledged formal education initiatives for clinicians, and those that
did, said this was typically directed at pharmacists rather than physicians. As one participant
mentioned, “It's difficult for physicians to commit to formal training ...” (Physician). Lastly, the
power of the patient case, that matched patients of clinical staff, was mentioned often as a
noticeable influence. As another participant stated, “I think the first thing that was important was
[for] someone to hear a case report and say, ‘Oh, you know I have ten patients I can [think] of
that are in that exact same boat.’ So, I think after your first win, you become more confident.”
(Pharmacist)
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Innovation Participants
This discussion focused on how to directly engage with patients and through this, provide
education that may drive their own engagement with providers. A pharmacist participant said,
“We are hoping to have more engagement with patients through the electronic patient portal
where we can actually return results with associated education information…and potentially talk
to them about their results...” (Pharmacist) In line with this, a few participants noted the success
of patient self-advocacy for testing saying, “Getting the patient to advocate to their provider, in
a lot of ways would be more effective. Right now our model is relying on providers…but if you
are advertising to patients, and they find it interesting, and they ask the provider about it, it's
going to be difficult for the provider to ignore.” (Pharmacist)
External Change Agents
Widely cited by nearly every participant was the role of CPIC members and the
accompanying guidelines produced by the group. As one physician said, “I’d say CPIC
guidelines have been enormously helpful. Having a guideline written by experts outside of
[redacted]. That external validity of the summary of the literature, and with a stamp that this is a
high level of evidence, is really helpful.”(Physician) The role of peer institutions with similar
EHR programs was also identified by a few participants as a positive influence on their success.
A pharmacist participant said, “You need someone whose been there and done it to ask some
questions of, particularly if they’re on your same EMR platform, that’s hugely helpful.
(Pharmacist) Table 3 below includes additional verbatim quotes from the Planning construct and
each of the Engaging sub-constructs.
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Executing Construct
A nearly ubiquitous issue in this part of the discussions was the issue of EHR
improvements and IT personnel availability. A pharmacist participant said, “I think the biggest
issue is there is no dedicated IT FTE for pharmacogenomics. It's me borrowing people's time to
do clinical decision support. So it goes into a bucket with every other IT request and things
sometimes move quickly, things sometimes move slowly.” (Pharmacist) Tangentially related to
this was the importance getting provider feedback regarding the workflow changes being made
with the implementation of pharmacogenomic testing programs. Frustration with a lack of this
was described by a participant:
“I think failure to understand the clinical infrastructure is the biggest difficulty and my
big frustration. My suggestion is to have the clinician champions go through and map the
process from beginning to end because otherwise trying to implement a program that is
not consistent with clinical practice, how things happen on a day to day basis…it just
does not work.” (Physician)
Understanding current workflow is crucial for effective integration of a new technology
like pharmacogenomics, but several participants emphasized incorporating resilience into an
implementer’s mindset. In this case, the term resilience here is best explained through this quote:
“So, one of the first early lessons that I learned was just because you think you might use this in
this particular service, they may have other ideas. So, one, you have to learn you might have to
be patient, an avenue will open up [with] someone else who you didn’t even expect to step
forward”. (Pharmacist)
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Reflecting and Evaluating Construct
Thematic material in this construct was dominated by the finding that most programs had
few goals beyond the directive to put a pharmacogenomics program into place. As one scientist
mentioned, “They wanted to launch a pharmacogenomics service that would be helpful to
clinicians and beneficial to patients. They didn’t feel like they needed to do it as a research
project to prove outcomes or to prove cost effectiveness. They really just wanted to get it into
clinical care first and foremost.” (Scientist) The “get it going” mentality seemed to be driven by
safety at its core, as a pharmacist mentioned, “The goal of the program, the primary goal, is
patient safety focused- or, medication safety focused.” (Pharmacist)
In the absence of traditional clinical outcomes, there were other important process
metrics that were incorporated into many programs. According to a pharmacist participant:
“We did have some quantitative goals. We still do. We’re supposed to be showing that we
have a higher percentage of prescribed drugs that are informed by pharmacogenetics,
basically every year. But we did leave the objectives of the protocol quite broad and
loose so that we would be able to continue to do the implementation without necessarily
meeting very hard specific goals.” (Pharmacist)
Table 4 below includes additional verbatim quotes from the Executing and Reflecting &
Evaluating constructs.
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4. DISCUSSION
This study represents one of the first primary data studies to qualitatively assess the
perspectives of the leading voices in the clinical implementation of pharmacogenomics. Also,
this is the first study to apply the rigor of an implementation science framework to
pharmacogenomics. The core finding from the Planning construct was the idea that for
successful implementation you must first do the appropriate due diligence on the clinical services
and clinicians themselves prior to engagement. Following from this, several participants noted
the importance of getting an “early win” to demonstrate to leadership that you can accomplish
something tangible. It is also important to recognize the limitations of pharmacogenomics at your
institution. A narrow, high-evidence focus will prevent a novice program from overselling and
causing frustration in the future. The discussion of formal oversight also brought to light several
important considerations. First, oversight covered the spectrum from formal committee to very
informal, ad-hoc processes. However, it is important to note that there always remained some
type of process. While it is unsurprising that newer programs may lack formal oversight, it was
surprising to note that some of the most mature programs also lacked formal oversight. This
seemed to be a product of pharmacogenomics folding into larger genomic initiatives with their
own oversight processes.
Across the sub-constructs of the Engaging construct there was a clear focus on the
importance of institutional leadership supporting the implementation. This took shape through Csuite executives who found particular value in pharmacogenomics, visionary clinicians, or in a
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broader sense, a cultural shift to one where genomics was integral to all clinical care. At a more
detailed level, participants widely noted that having a clinical champion in each service was
essential to communication with the broader clinical network. Having a single individual to
contact who then forwarded the information to colleagues was both successful and timesaving.
However, this did not always have to be a physician-to-physician conversation. Many
participants noted that they utilized the clinical pharmacist on service as a communication
conduit to prescribers. From both pharmacists and physicians, there was strong opinion that all
pharmacists should have some tacit knowledge of pharmacogenomics and be ready to interact
with any prescriber when needed.
The lengthy discussions on provider communication led to the ubiquitous opinion that
informal, high-touch interactions were optimal. Terms such as “carpet-bombing” and “traveling
roadshow” quickly showcase this sentiment. This was typically operationalized through grand
rounds, lunch-and-learns, and even the classic “water-cooler” conversation. The importance of
the patient case or the patient-driven referral was also a catalyst of provider engagement in
pharmacogenomics.
The Executing construct discussion centered around clinical decision support and clinical
workflow. A common refrain was the need for more dedicated pharmacogenomic FTEs in the IT
profession. Interfacing these individuals with more frequent clinical feedback on CDS language
is essential to more effective workflow. Resilience should also be a part of every implementer’s
toolkit. Perspectives from our participants indicated that even though a first attempt might fail,
either opinions in the clinical service may change or a service you did not expect might come to
you.
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The Reflecting & Evaluating construct revealed a prevailing focus on patient safety and
programmatic goals to simply establish and maintain a clinical pharmacogenomic service.
Explicit data collection and measurement that did exist were not targeting clinical or economic
outcomes, but rather they were process-based metrics for how pharmacogenomics was being
used and how providers were responding to the addition of pharmacogenomic decision support
alerts in the EHR. In some instances, these initial goals were simply to move pharmacogenomic
results into discrete data fields and enable metric tracking. This is an essential step towards
outcomes-based studies that reflect real-world clinical practice and decision making.
This study used a popular implementation science framework, the CFIR, to address
several issues, including the need for greater clinical education in genomics and improvements in
clinical workflow and decision support, that were identified as important for the sustainability of
genomic medicine and pharmacogenomics. We decided to focus our efforts on the foundational
concept of sustainability in implementation science because it has received increasing attention
as one of the most important, yet more misunderstood foundations of implementation science.35
The study is somewhat limited due to the unbalance in the professional credentials of the
respondents. This unbalance is, however, indicative of the current leadership and programs in the
field. Also, focusing only on the CFIR Process domain excludes the potential application of other
CFIR domains to this topic. Future research should explore other CFIR domains for their insights
into clinical pharmacogenomic implementation.
Our decision to study the CFIR Process domain and its operationalization herein can be
further understood by connecting this domain with sustainability. Sustainability has been
conceptualized not just as an outcome or metric of a successful implementation, but also as a
cyclical “change process” that provides adaptability in pre-implementation stages such as
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planning and organizational support, as well as a concomitant process to the implementation
itself .36,37 Indicators of sustainability have been operationally defined as maintenance,
institutionalization, and (infrastructure) capacity building.38 Capacity-building in the
sustainability planning model is represented by factors that apply to both physical and human
infrastructures which include: structures and linkages, champions and leadership, resources,
policies and procedures, and expertise.29,36 The nature of the constructs and sub-constructs of the
Process domain are characterized by a similar set of terms.
Sustainability in pharmacogenomics is particularly important when we consider what
several participants described as a research-to-clinical progression of the program. Initial internal
or extramural funding supported many programs with the expectation that the program would be
self-supporting in the future. The formal implementation programs in pharmacogenomics
represented by our participants for pharmacogenomics have been leading the way in the clinical
use of genomic medicine and development of the resources necessary to support the delivery of
results.19,39 However, most health care institutions in this country do not have robust clinical
pharmacogenomic programs and current implementers of pharmacogenomics have expressed
concerns of handoffs outside of their own program.15 The potential ‘down-the-road implications’
of pharmacogenomic results on future therapeutic decision making will require that local health
systems adopt and implement their own programs. They must do this carefully and sustainably
from the start because most will not have the luxury of robust institutional or extramural support.
Armed with a deeper understanding of the Process domain and the infrastructure
capacities necessary to achieve sustainability of the program, future implementers of clinical
pharmacogenomics now have a list of factors to consider in designing their own programs with
sustainability at is core. Moreover, they have the ability to avoid some of the roadblocks and
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challenges these innovators have faced. Future work should examine more closely the economic
implications of revising an initial implementation plan. Future resource-limited institutions must
be able to prioritize the initiatives to establish a clinical and operationally effective
pharmacogenomic program while keeping costs to a minimum.
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APPENDIX 1. – SEMI-STRUCTURED INTERVIEW GUIDE
Thank you for taking the time to speak with me today. My name is Nick Keeling and I am the
principal investigator on this project. I want to inform you that I’ll be recording this interview,
and that quoted material may be used for a future publication. Your name and the name of your
organization will always remain confidential. We expect this interview to take approximately 45
minutes. You may withdraw at any time if you wish.
You were asked to be a part of this study because of your clinical, research, and implementation
experience with pharmacogenomics. Please answer these questions as thoroughly as possible.
We believe that your insights can guide future implementers of pharmacogenomics and lead to
greater standardization across different care settings.
Do you have any questions for me before we begin?
1. To get started, tell me a bit about your general organizational roles: clinical, research, and
administrative.
2. Do you know how your organization became involved in using pharmacogenomics in
routine patient care? When did it begin?
o Is pharmacogenomics the primary genomic related initiative? Why was
pharmacogenomics chosen over something else?
PLANNING
3. What were the steps involved in getting a plan in place for implementing the
pharmacogenomics program?*
o Who was involved in the planning process?
4. Tell me how it was communicated to clinicians, leadership, research
5. Was a formal committee put together to direct the implementation of
pharmacogenomics?*
o Tell me about its structure. How and when was it was organized?
ENGAGING
Formally Appointed Internal Implementation Leaders
6. Who has led the implementation of the pharmacogenomics program at your organization
(physicians, pharmacists, others clinical or non-clinical personnel)?*
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7. Are there certain groups that you wish had been included at the beginning that would
have made implementation more successful?

Opinion Leaders
7. Who were the key influential individuals (or opinion leaders) to get on board with
implementing a pharmacogenomics program?
o To what extent have these individuals influenced others' use of
pharmacogenomics? Success of the implementation?
Champions
8. Other than formal implementation leadership, what people in your organization have
taken on the role of a ‘champion’ for pharmacogenomics?
o How has this supported the implementation? What has been most productive?
o Who else is needed to ‘champion’ this successfully?
1. More administrators, advanced practice, genetic counselors?
Key Stakeholders
11. What steps have been taken to encourage clinicians to use pharmacogenomics?*
o What was the most successful way to communicate with or approach them?
o What types of training were offered to your clinicians?
Innovation Participants
12. What has been the communication strategy for getting the word out about
pharmacogenomics to patients and families?
o What certain communication processes have worked best?
External Change Agents
15. What role, if any, have peers, external organizations, research groups, or individuals
played in helping execute the pharmacogenomics program at your organization?*
o How were/are they involved? What kinds of activities were/are they doing?
EXECUTING
8. Has your pharmacogenomics program been implemented according to the initial plan?
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9. Were there aspects of the plan that created difficulties in the implementation of the plan?
10. What were some of the more significant revisions or refinements to the plan that were
developed during the implementation process?
o How were these shared with other key stakeholders?
REFLECTING & EVALUATING
16. Were there explicitly set goals you and your team developed in relation to the
implementation of your pharmacogenomics program?*
o Were these communicated beforehand? To whom?
o What goals still remain?
17. What data are collected/measures tracked to evaluate progress toward the goals?*
o Are these clinical, economic, or descriptive?
18. Have you collected structured feedback from clinical staff on their experiences with
pharmacogenomics?
o Was it positive? Negative? Neutral?
o Was this collected with the intent to publish? Or for internal use?
1. If yes, was this published and in what setting?
2. If no, what was this rationale?
19. How have these outcomes been distributed to implementation leaders and other
appropriate stakeholders? Mode? Frequency?
o How has this been used to improve practice?
20. What experience has made the biggest impact in improving the delivery of
pharmacogenomics?
That is all the specific questions I have for you today. Is there anything else you would like to
add to our discussion? Feel free to be as broad or detailed as you’d like.
Thank you so very much for your time.
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APPENDIX 2. – INVITATION EMAIL FOR SURVEY AND INTERVIEW

Good Morning,

This is an invitation to participate in ongoing academic research focused on the implementation
and sustainability of pharmacogenomics. (If the potential respondent was nominated through
snowball sampling the following sentence will be added: “You were nominated by ______ as an
appropriate person to participate in this research.)
This research includes a 5 minute survey and telephone interview expected to last around 45
minutes. The interviews will take place between XXX and XXX. The interviews will be
recorded, but your name and organization will remain confidential. We do not believe there are
any risks associated with this research. You do not have to take part in this study and you may
stop participating at any time.
Please click the link just below to complete the survey. Your responses to this survey will not
affect your eligibility to participate in the interview.
<<<Qualtrics link>>>

Please fill out this confidential Doodle poll with your preferred time for the interview.
<<<Doodle poll link>>>

Please contact Nick Keeling at nick.keeling@stjude.org if you have any questions. Nick will
reach out to you with a calendar invite at one of your available times.
As a reminder, this study has been approved by The University of Mississippi’s Institutional
Review Board (IRB). If you have any questions, concerns, or reports regarding your rights as a
participant of research, please contact the IRB at (662) 915-7482 or irb@olemiss.edu.
I have read and understand the above information. By completing the survey and interview I
consent to participate in the study.
Thank you very much for your time.
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APPENDIX 3. – ONLINE DEMOGRAPHIC SURVEY
Thank you for your participation in this research. Responding to this survey serves as your
consent to participate. Please answer all the questions. Your name and organization will always
remain confidential.
1. Are you at least 18 years of age or older?
o Yes
o No (not eligible to continue)
2. Are you a...?
o Physician (MD or DO)
o Pharmacist (PharmD or RPh)
o Clinical research scientist (PhD)
o Other, please specify ________________
3. Are you at an academic institution?
o Yes
o No
4. Please select any pharmacogenomic research groups/networks/consortiums you are either
involved with or a member of (select all that apply)
o CPIC
o IGNITE
o eMERGE
o PGRN
o PharmVar
o Other, please specify ___________
5. How long has your institution been implementing pharmacogenomics into clinical
service?
o Less than 1 year
o 1 – 3 years
o 3 – 5 years
o More than 5 years
6. How many germline variants do you currently have in clinical service?
_________variants
7. Please select the type(s) of clinical pharmacogenomic testing your institution conducts
(select all that apply)
o Single-gene genotyping
o Multi-gene genotyping
o Exome sequencing for pharmacogenes
o Genome sequencing for pharmacogenes
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8. Is most of your clinical pharmacogenomic testing done…
o Preemptively
o Reactively
o Both
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APPENDIX 4. – EMAIL TO ASSIST IN SNOWBALL SAMPLING

Good Morning,

Thank you again for participating in the recent interview on pharmacogenomic implementation.
We are reaching out to you again today to ask you to nominate one or more additional potential
respondents to complete the same interview. You are under no obligation to nominate additional
participants and your choice has no bearing on your previous response.

Please respond to this email with the name, credential, professional job title, and best contact
email for your nominated respondent(s).
By responding to this email with your nominations you are also consenting for us to reveal your
name to your nominee(s).

Please contact Nick Keeling at nick.keeling@stjude.org with any questions.

As a reminder, this study has been approved by The University of Mississippi’s Institutional
Review Board (IRB). If you have any questions, concerns, or reports regarding your rights as a
participant of research, please contact the IRB at (662) 915-7482 or irb@olemiss.edu.

Thank you very much for your time.
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SECTION III.

SUSTAINABLE DELIVERY OF PHARMACOGENOMICS IN
PRIMARY CARE: TESTING THE POTENTIAL FOR PHYSICIANPHARMACIST COLLABORATION
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1. BACKGROUND
Implementation programs for pharmacogenomics, and studies of genetic variation and its
influence on drug response, continue to increase in number and public funding.1 As barriers are
overcome, the most challenging obstacles to the continued success of this field of study become
clearer. Two such obstacles preventing broader use of “clinical pharmacogenomics”, a term used
to reflect its application in clinical practice, are provider knowledge/education and testing
reimbursement by insurers.2-6 In fact, the Implementing Genomics into Practice (IGNITE)
Sustainability Working Group recently identified the need for expanded (pharmaco)genomic
education for providers as the most important construct for the sustainability of the science.5
The noted insufficiencies in provider knowledge about pharmacogenomics and
preparedness to use these results reaches back several years and stubbornly persist.7-10 Studies
from 2012 found that although nearly all (98%) of physicians believed the patient’s genetic
profile influences their response to drug therapy, 90% felt inadequately informed on testing
availability and application, and approximately 80% of primary care physicians (PCPs) had
never ordered a pharmacogenomic test.7,11 More recent work shows limited progress in the
number of tests ordered, with around 30% of physicians reporting having ordered or
recommended a pharmacogenomic test in the past six months.9 Despite this improvement, family
physicians, a first touch-point for many patients, still have a lower likelihood of adopting
pharmacogenomics.9 This compounds concerns from physicians based in academic settings,
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actively engaged pharmacogenomic implementation, around patient hand-offs to providers
outside of these institutionally based pharmacogenomics implementation programs.12
Despite some of these shortcomings, physicians from pharmacogenomic programs within
the IGNITE network are reporting improvements in adequate training and confidence regarding
the use of pharmacogenomics.10 Physician attitudes on the clinical usefulness, training and
preparedness, and awareness of resources were all statistically significantly more positive for
pharmacogenomics as compared to disease genetics.10 Being able to find and use reliable sources
of information to understand and communicate risk also had higher reported odds for
pharmacogenomics compared to disease genetics.10 However, confidence in the ability to use
pharmacogenomic results remained low with 30% of physicians responding as such.10
Parallel research with pharmacists has demonstrated a pharmacogenomic education need
for these providers as well. While nearly all pharmacists had positive attitudes toward
pharmacogenomics, and more than half (57%) believe it is their role counsel patients on this
information, less than 20% feel their training had been adequate to deliver this information.13
Early assessments of pharmacists as providers of pharmacogenomics found that 85% felt they
should be knowledgeable and 65% said they should be capable of providing information on
appropriate use of testing.14
The pharmacy profession has also taken lead in the education of providers through
pharmacogenomics curriculum development and continuing education programs.15-17
Researchers from the Mayo Clinic shared their approaches to achieving competencies in
pharmacogenomics for healthcare professionals. In particular, they highlighted their work with
educating pharmacists, the unmet need to craft “genomic nurses”, and the overall importance of
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transdisciplinary care in this field.18 Successful pharmacogenomics implementation programs at
academic health systems have been delivered in a highly collaborative infrastructure, several of
which have been led by senior pharmacists.4,19,20 Additionally, two of the largest professional
pharmacy organizations, the American Society of Health-System Pharmacists (ASHP) and the
American Pharmacists Association (APhA), have both put out official positions and statements
in the past decade on the role of the pharmacist in the delivery of pharmacogenomics.21,22
Specifically, they highlight the unique skills and abilities of pharmacists, their relation to the
delivery of pharmacogenomics, opportunities for integration into medication therapy
management (MTM) services, and call on the educational community to prepare pharmacists to
apply pharmacogenomic information to therapeutic decision-making.
Pharmacist-physician collaboration in pharmacogenomics
Pharmacists possess a clinical skill set complementary to the delivery of
pharmacogenomics with their specialized training in the pharmacokinetics and dynamics of
medications, their interactions, and dosing, all of which can be applied to reduce adverse events
driven by drug-gene interactions.23 The noted successes of institutional pharmacogenomic
programs led by senior pharmacists has resulted in recent calls to study the role of the pharmacist
as the local ‘clinical champion’ in greater detail.24
Collaborative practice agreements (CPAs) or collaborative drug therapy management
programs (CDTMs) between physicians and pharmacists may be one way to improve the
delivery of pharmacogenomics through a transdisciplinary structure in primary care, and to
address those constructs most important to the sustainability of genomic medicine.: expanding
provider education and improving the integration of genomic information into workflow.5 CPAs
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and CDTMs expand pharmacists’ involvement in patient care by providing a defined protocol
under which pharmacists may complete assessments, provide counseling, order diagnostic tests,
and manage the patient’s drug regimen.25 It is important to recognize that legislation pertaining
to CPAs and CDTMs differs from state to state. Pharmacists may enter into formal collaborative
practice agreements in 48 states and the District of Columbia.26 Of these states, 38 allow
pharmacists to initiate drug therapy and 45 allow them to modify an existing therapy. These
allowances must be explicitly stated in the agreement, and in 29 states there is a requirement to
specify which medications or disease states the pharmacist can manage. Additionally, 31 states
currently allow the pharmacist to order and interpret laboratory tests, which could include
pharmacogenomics.26
A meta-analysis of US pharmacists’ involvement in a patient care team found significant
improvements in both therapeutic, safety, and humanistic outcomes over comparative services.27
Recent studies with physicians in active supervisory roles of a clinical pharmacist in a CPA have
reported better clinical outcomes, more efficient medication management, clinically helpful
recommendations, improved efficiencies in care, and an advanced learning environment which
includes newly accessible drug knowledge.28,29 Limited reimbursement and billing
considerations are the most frequently reported barriers; as well as worries over a loss of control
and confidence in the pharmacists’ clinical.29,30 Under four percent of responding primary care
physicians indicated they would not be accepting of clinical pharmacist practitioners.29 However,
previous literature has shown that 25% of pharmacists feel that acceptance by primary care
physicians is a barrier to collaborative practice.
Family physicians and community pharmacists in Canada, a country where the traditional
function of a pharmacist more closely mirrors the CPA function of US pharmacists, also report
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contrasting perceptions of importance in the function of community pharmacists.31 There was
44% agreement for the pharmacist function “providing advice regarding drug interactions” and
25% for both “assisting in medication dosage adjustment” and “providing drug information to
help select a medication”, suggesting there remains space for imporvement.31 Economic analyses
of pharmacist-physician collaborations have also reported positive (cost-saving) findings in
addition to clinical improvements across various scenarios.32,33
The role and responsibilities of the pharmacist in the delivery of clinical
pharmacogenomics has been also been examined. A prospectively designed pilot study measured
the clinical support of two different pharmacist models (in-house vs. on-call) at two primary care
clinics.34 A pre-test assessment among the primary care physicians showed that over 90% felt
having assistance in interpretation of pharmacogenomic results would increase the likelihood of
them ordering a test. Eighty-nine percent thought that the pharmacist or the geneticist/genetic
counselor would have “some or a large role in delivery pharmacogenomic testing”.34 Results
from the pilot study also showed that the physical presence of a pharmacist enhanced the preheld perspectives.34 Interestingly, when the ‘continued test utilization’ was assessed, one-third of
providers reported that they were ‘very or somewhat likely’ to continue ordering. However,
when the pharmacist was removed from the clinic there were no new pharmacogenomic tests
ordered.34 This illuminates the role that the pharmacist has in the sustainment of
pharmacogenomic test ordering.
Pharmacist appear well-positioned to assist in the clinical delivery of pharmacogenomics.
The positive outcomes of using pharmacists in primary care teams, success of pharmacist-led
pharmacogenomic implementation programs, a pharmacy profession leading new educational
initiatives in pharmacogenomics, and a scope of practice in many states enabling pharmacist
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involvement in pharmacogenomics provide support for this statement.35 Although most
physicians perceive collaborating with a pharmacist as being beneficial to their practice and
patients, there is little consensus from physicians, and a need for further study, on the level of
clinical responsibility they should have, including the pharmacist role in the delivery of clinical
pharmacogenomics.
Designing the implementation and delivery of pharmacogenomics in the primary care
setting could benefit from similar collaborative infrastructures as those outlined in the pilot
studies. The challenge before the pharmacogenomics community will be to design these
implementations with a solid understanding of the factors impacting its longer-term
sustainability. As such the objective of this study is to understand how primary care physicians
currently view the use of pharmacogenomics in practice and how clinical collaboration with
pharmacists may influence their perspective.
Implementation science and study hypotheses
Previous research has provided the field of implementation science, the study of methods
to improve the adoption of evidence-based research and practice, with a “working taxonomy” of
eight outcomes to use when evaluating successful implementation.36,37 Three of these outcomes:
acceptability, appropriateness, and feasibility, were recently developed into measures with their
psychometric properties having been assessed.38
•

Acceptability is “personal”: individual judgments of ‘clinical pharmacogenomics’ based
on differing needs, preferences or expectations.37

120

•

Appropriateness is “technical or social”: judgments based on the efficacy of the ‘clinical
pharmacogenomics’ achieving some purpose under certain conditions (type of patient,
culture, infrastructure, etc).37,38

•

Feasibility is “practical”: judgments based on the perceived ease of implementing
‘clinical pharmacogenomics’ given the individual’s necessary resources (effort, time, or
money) and unique circumstances.37,38

The three measures of these implementation outcomes are the Acceptability of Intervention
Measure (AIM), the Intervention Appropriateness Measure (IAM), and the Feasibility of
Intervention Measure (FIM).38 High scores on these outcome measures provide researchers an
early indication of the likelihood that staff will adopt a new ‘something’, or if more work is
needed to increase scores in one or more outcome measures. Standardizing the use of
implementation outcomes has been seen as a critical step for conceptualizing and evaluating the
success of a new intervention.39 The outcomes serve as both indicators of a successful
implementation and intermediate outcomes related to the eventual clinical, economic, or social
outcomes. Without a successful implementation, the intervention or treatment is likely to be
ineffective.39 To make clinical pharmacogenomics effective to patients, we must ensure the
providers delivering the intervention are doing so in such a manner to facilitate its success.
Further, these standardized measures make future meta-analyses on this subject possible.
Using these measures, we aimed to collect primary care physicians’ (PCPs) current opinions
on the acceptability, appropriateness, and feasibility of pharmacogenomics in their primary care
practice. An exploratory analysis was conducted to identify what demographic variables were
significant predictors of the baseline AIM, IAM, and FIM scores. As the central analysis herein,
we aimed to test the appropriateness and feasibility of delivering of clinical pharmacogenomics
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across experimentally manipulated scenarios that reflect realistic, potential variations in the roles
of physicians and pharmacists. The following research questions and hypotheses were tested:
Research question 1: What level of pharmacist involvement in the functions of delivering
clinical pharmacogenomics do primary care physicians find most appropriate?
Hypothesis 1. The appropriateness of clinical pharmacogenomics will be positively associated
with greater levels of pharmacist involvement and collaboration.
Hypothesis 1a. PCPs will consider clinical pharmacogenomics more appropriate when the
pharmacist is located in the clinic.
Hypothesis 1b. PCPs will consider clinical pharmacogenomics more appropriate when the
pharmacist selects and orders the pharmacogenomic test.
Hypothesis 1c. PCPs will consider clinical pharmacogenomics less appropriate when the
pharmacist modifies the medication regimen and counsels the patient.
Research question 2: What level of pharmacist involvement in the functions of delivering
clinical pharmacogenomics do primary care physicians find most feasible?
Hypothesis 2. The feasibility of clinical pharmacogenomics will be positively associated with
greater levels of pharmacist involvement and collaboration.
Hypothesis 2a. PCPs will consider clinical pharmacogenomics more feasible when the
pharmacist is located in the clinic.
Hypothesis 2b. PCPs will consider clinical pharmacogenomics more feasible when the
pharmacist selects and orders the pharmacogenomic test.
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Hypothesis 2c. PCPs will consider clinical pharmacogenomics more feasible when the
pharmacist modifies the medication regimen and counsels the patient.
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2. METHODS
Study design
This study used a quantitative survey methodology that included a series of experimental
vignettes. Experimental vignette surveys typically consist of short narrative scenarios or lists of
attributes manipulated via the included levels. This allows the researcher to exert a level of
experimental control, excluding variables that might confound results, and establish causal
relationships if they exist.40 Incorporating vignettes has been shown to be a practical
methodology for the assessment of clinical practice scenarios.41
Survey instrument
The survey consisted of two main sections: the first captured participant demographics,
practice characteristics, data on the respondent’s practice integration with pharmacists and
familiarity with collaborative practice, and the respondent’s experiences and perspectives on
clinical pharmacogenomics. The second was the experimental vignette portion which will be
described in more detail below.
Several practice characteristic questions were adapted from a survey instrument
developed by the National Cancer Institute for evaluation of primary care physician
recommendations and practice for cancer screening.42 Changes made included the altering the
type of response (multiple choice vs. open response) or decreasing number of multiple-choice
options available to the respondent. Three items to assess perceived knowledge of
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pharmacogenomics in this section come from the IGNITE Common Measures Working Group
“Provider Baseline Knowledge of Genetic Testing Survey” and are available online in the
IGNITE Spark Toolbox.43 These items were chosen so that a comparison of respondents
perceived knowledge of using pharmacogenomics could be made to their awareness of the
leading pharmacogenomic resources such as the Clinical Pharmacogenetics Implementation
Consortium (CPIC) and the Pharmacogenomics Knowledgebase (PharmGKB). Also, a baseline
assessment of ‘acceptability’, ‘appropriateness’, and ‘feasibility’ of clinical pharmacogenomics
was measured using the AIM, IAM, and FIM scales. The term ‘clinical pharmacogenomics’
replaced the word “intervention” in the author’s original scales.38 For the IAM and FIM scales,
the language ‘in my primary care practice’ was added. The authors explicitly state in the
psychometric study that the items were made as “general as possible” to facilitate adaptation to
specific contexts or clinical problems.38 Each item is measured using a 5-point Likert-type
response format and scores were created by averaging responses for all items in each scale.
Independent variables
The vignette portion of the survey was a 2 x 2 x 2 between-subjects experimental design.
Table 1 describes the levels of the factors in more detail.

Table 1. Experimental vignette manipulations
Factors

# of levels

Description of levels

Pharmacist location

2 (b/w)

•
•

In the clinic
Outside the clinic

Selects and orders pharmacogenomic
test

2 (b/w)

•
•

Pharmacist
Physician

Manages results and modifies the
patient’s medication regimen

2 (b/w)

•
•

Pharmacist
Physician
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The factor ‘pharmacist location’ mirrors the two pharmacist arms of the Haga et al. trial
discussed previously.34 The remaining factors represent the varying responsibilities a pharmacist
might have with the delivery of pharmacogenomic testing in a collaborative practice
environment. These include the responsibilities of selecting and ordering the test and the
subsequent management and use of the results for modification of drug therapy. Table 3 shows
each factor and its corresponding levels, as well as a description of the levels. The survey was
pre-tested with two primary care physicians reflective of our target sample and slight revisions to
clarify the language in the vignettes were made based on this feedback. The exact language of
the vignettes can be found at the end of Appendix 1.
Dependent variables
The outcome measurement following the experimental vignettes was a reassessment of
the IAM and FIM scales with the language “delivered this way” inserted into the original
measure to better reflect the information presented in the vignettes. Only the IAM and FIM were
selected for measurement following the vignettes because the aforementioned ‘criterion’
descriptions of these two scales better capture the objective to understand the potential for
collaborative practice in the delivery of clinical pharmacogenomics. The same adaptation to
measures described previously was maintained in the reassessment to reinforce the focus on the
appropriateness and feasibility of clinical pharmacogenomics to their practice broadly. The AIM
scale was excluded from the vignette because the language of the items was not sensical given
the objective and focus on collaborative practice environments.
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Data collection and sampling methods
A power analysis indicated that to achieve a power of at least 0.90 to detect medium main
and interaction effects with a significance level of 0.05, a total of 176 respondents were needed.
Given our 2x2x2 design, this required 22 cases for each of the eight treatment groups. To
facilitate this data collection, Reckner Healthcare (Chalfont, PA) was engaged to recruit a sample
of primary care physicians (family medicine or internal medicine) from their available panel. An
invitation email consistent with Reckner Healthcare’s policies was distributed to eligible primary
care physicians on their panel. These physicians were not offered any incentive but were
provided with a summary of the results upon analysis (APPENDIX 2). Participants were
randomly assigned to one of the eight treatment groups upon beginning the survey and data
collection continued until the required 22 cases per group was achieved.
Analysis procedure
A descriptive analysis provided data on general and pharmacist-related practice
characteristics, as well as mean scores on the AIM, IAM, and FIM scales prior to any
manipulation. Scale values on these three outcomes range from 1 to 5, have been treated as
continuous variables for analysis, and averaged for a single score. Higher scores indicate greater
levels of acceptability, appropriateness, or feasibility. Three separate multiple regressions were
used to assess if there were significant predictors of the baseline mean scores of the AIM, IAM,
and FIM without experimental manipulations. Predictors included questions related to the
importance of pharmacists in clinical care, perceived pharmacogenomic knowledge as measured
by the three items from the IGNITE Spark Toolbox, and the average score across the familiarity
with CPIC and PharmGKB. These predictors were included because of their association with
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provider education and pharmacist collaboration. To test the effect of the independent variables
on the scores for the IAM and FIM scales after vignette manipulation, the data were analyzed
using a three-way analysis of variance (ANOVA) procedure for each of the two dependent
variables. All tests were conducted at the α=0.05 level of significance.
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3. RESULTS
The number of respondents to achieve our desired power and to satisfy equal
stratification across our eight groups was achieved with a final sample of 177 family practice or
internal medicine physicians. Data collection was closed as soon as 22 respondents were
collected for each group. One group or vignette received an extra respondent likely due to
another respondent starting the survey and finishing later. This extra respondent was excluded
from any analysis.
Nearly two-thirds of respondents were family medicine physicians and close to 90%
having practiced more than 16 years. Most were either practice owners or associates and worked
in practices with 30 or fewer physicians. About a third of respondents worked in multi-specialty
clinics. On average, physicians reported that collaborating with a pharmacist in their primary
care practice fell between somewhat and moderately important (3.47 on a 5-point Likert-type
item). Physician familiarity with CPAs scored between slightly and somewhat (2.5 out of 5). Just
over three-quarters of physicians indicated that they only interact with a community pharmacist,
the remaining responded that they had a full-time or part-time pharmacist that worked in the
clinic. Fifteen percent of physicians indicated that pharmacist involvement was part of a formal
CPA. Of those involved in a formal CPA, 85% granted the pharmacist full access to patient’s
medical records.
Several questions were asked related to the physician’s exposure and experience with
pharmacogenomic testing in their practice and revealed some interesting findings. Familiarity
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with using pharmacogenomic information scored between slightly and somewhat familiar (2.63
out of 5). On the three items from the IGNITE Spark Toolbox scores were slightly higher than
overall familiarity, ranging from 2.96 on the “my training has prepared me to treat patients
whose genetics place them at high risk for medical conditions” item and a 3.18 on the “I am
confident in my ability to use the results of a pharmacogenomic test” item as well as the I can
find/use reliable sources of the information I need to apply pharmacogenomic testing while
caring for patients” item.43 Scores on the items assessing familiarity with Clinical
Pharmacogenetics Implementation Consortium (CPIC) and Pharmacogenomics Knowledgebase
(PharmGKB) were much lower, 1.61 and 1.59, respectively. Most respondents (66%) have never
had a patient ask about pharmacogenomics and just over half had never used pharmacogenomic
information in patient care. Insurance coverage and reimbursement remain top barriers to more
widespread use. Close to 80% of physicians indicated that removing selection and ordering of
the test from clinical workflow would make delivery more feasible. Appendix 3 contains
complete tables of respondent demographics and practice characteristics.
Baseline assessment of the implementation outcomes from Weiner et al., acceptability
(AIM), appropriateness (IAM), and feasibility (FIM) scales, are provided below in Table 2.38
Scores on the AIM were the highest across the three with a slight drop on the IAM scale, and a
further drop on the FIM. Only the last item in the FIM scale scored, on average, below a 3 on a
5-point Likert-item.
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Table 2. Implementation Outcome Measures Applied to
Clinical Pharmacogenomics
(1 = Strongly disagree, 5 = Strongly Agree)

Mean

Acceptability of Intervention Measure (AIM)
Clinical pharmacogenomics meets my approval

3.72

Clinical pharmacogenomics is appealing to me

3.77

I like clinical pharmacogenomics

3.62

I welcome clinical pharmacogenomics

3.73
Overall Mean = 3.71

Intervention Appropriateness Measure (IAM)
Clinical pharmacogenomics seems fitting in my primary care
practice
Clinical pharmacogenomics seems suitable for my primary care
practice

3.45
3.48

Clinical pharmacogenomics seems applicable to my primary care
practice

3.60

Clinical pharmacogenomics seems like a good match for my
primary care practice

3.49
Overall Mean = 3.50

Feasibility of Intervention Measure (FIM)
Clinical pharmacogenomics seems implementable in my primary
care practice

3.19

Clinical pharmacogenomics seems possible for my primary care
practice

3.54

Clinical pharmacogenomics seems doable in my primary care
practice

3.36

Clinical pharmacogenomics seems easy to use at my primary care
practice

2.99
Overall Mean = 3.27
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The ANOVA results from the experimental vignette manipulation can be seen in Table 3.
Recall, only the IAM and FIM scales were used as the dependent variables following the
vignettes.
Table 3. ANOVA Results for Dependent variables (n=176)

Independent variables

Dependent Variables
Intervention
Intervention
Appropriateness
Feasibility
F ratio (p value)
F ratio (p value)

Main effects
Location of pharmacist
Provider selecting and ordering test

1.132 (0.289)

0.947 (0.332)

2.310 (0.130)

3.004 (0.085)

Provider managing results and modify drug
therapy

0.59 (0.808)

0.008 (0.927)

2.897 (0.091)

1.069 (0.303)

4.272 (0.040)*

2.900 (0.090)

1.265 (0.262)

0.408 (0.524)

0.075 (0.785)

0.092 (0.761)

Two-way interactions
Location * Select-order
Location * Manage-modify
Select-order * Manage-modify
Three-way interaction
Location * select-order * manage-modify

* Significant at p < 0.05
There were no significant main effects, as well as no significant second-order interactions.
However, there was a significant first-order interaction between the location of the pharmacist
and the provider responsible for managing and modifying drug therapy. This was only significant
for the IAM scale dependent variable (F = 4.272, P = 0.040). Figure 1 below shows the plot of
this cross-over interaction. A simple effects analysis shows that if the pharmacist is managing
and modifying drug therapy their physical location does make a statistically significant
difference (F = 4.829, p = 0.029). If the physician is responsible for managing and modifying,
the location of the pharmacist does not make statistically significant difference (F = 0.492, p =
0.482).
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Figure 1. Two-way interaction of Location * manage-modify on appropriateness (IAM) scores

Although not significant at α = 0.05, two other potential cross-over interactions were
observed. The interaction effect of location of the pharmacist and the person responsible for the
selecting and ordering of the pharmacogenomic test on the IAM dependent variable was nonsignificant (F = 2.897, P= 0.091). The plot of this interaction can be seen in Figure 2. A similar
pattern emerges in this simple effects analysis as the previous one. If the pharmacist is
responsible for selecting and ordering, the location of the pharmacist did make a difference in the
appropriateness according to PCPs (F = 3.789, p = 0.053).
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Figure 2. Two-way interaction of location * select-order on appropriateness (IAM) scores

Another potential crossover interaction was observed between location and the persons
responsible for managing the test results and modifying therapy, but this time for the FIM scale
dependent variable (F = 2.900 P = 0.090). The plot for this interaction is shown in Figure 3.
Again, the simple effects analysis showed a similar trend although not as strong as the two
previous ones. If the pharmacist was responsible for managing and modifying, their location in
the clinic seems to have an impact on the feasibility of delivering pharmacogenomics to the
responding PCPs ((F = 3.569, p = 0.061)
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Figure 3. Two-way interaction of location * manage-modify on feasibility (FIM) scores

As such, both Hypothesis 1 and Hypothesis 2 are not supported. However, as shown
earlier, the presence of a statistically significant first-order interaction term changes our
interpretation of the main effects associated with Hypothesis 1a and 1c. All three hypotheses, 1a
– 1c, are not supported based solely on the main effects. All three sub-hypotheses from
Hypothesis 2 are also not supported based on their main effects. Although there was no
statistically significant first-order interaction terms for this outcome variable, the potential for
cross-over interactions on the basis of the cell means plots were observed and suggest that PCPs
do find delivering pharmacogenomics more feasible when the pharmacist is located in the clinic
and is responsible for managing and modifying drug therapy.
All three regression models with the baseline AIM, IAM, and FIM scores as dependent
variables were significant (P < 0.001). Their respective R2 values can be found in Table 4 along
with the full model results. With the baseline scores on the three implementation outcome scales
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serving as our dependent variables, the same three independent variables were significant across
the three models. These included an item measuring the importance of collaborating with a
pharmacist in the responding physician’s practice, as well as the perceived pharmacogenomic
knowledge and familiarity with pharmacogenomic resources variables. The only non-significant
variable included was actual pharmacist involvement in the primary care practice of the
responding physician. This was non-significant across all three models.
Table 4. Regression results of pharmacist and pharmacogenomic influences
on baseline AIM, IAM, FIM scores (n=176)
AIM
2
(R = 0.317)
F ratio (P value)

IAM
2
(R = 0.381)
F ratio (P value)

FIM
(R = 0.469)
F ratio (P
value)

0.289 (<0.0001*)

0.348 (<0.0001*)

0.298
(<0.0001*)

Full-time in the clinic

0.060 (0.397)

0.025 (0.711)

0.027 (0.664)

Part-time in the clinic

0.033 (0.623)

0.103 (0.104)

0.067 (0.256)

Perceived PGx knowledgeb

0.270 (<0.0001)*

0.292 (<0.0001*)

0.346
(<0.00001*)

0.163 (0.030)*

0.150 (0.036*)

0.251
(<0.0002*)

Importance of collaborating with a
pharmacist in the primary care
practice

2

Pharmacist involvement in primary
care practicea

Familiarity with PGx resourcesc

std β (p value)
a

Dummy variables: reference group is working with a community pharmacist only
Average score across the three items included from the IGNITE Spark Toolbox
c
Average score across familiarity with CPIC and PharmGKB questions
* Significant at p < 0.05
b

136

4. DISCUSSION
The focal analysis of this study showed that when a pharmacist responsible for managing
pharmacogenomic results and modifying drug therapy, primary care physicians found this to be
significantly more appropriate when the pharmacist was physically located in the clinic with the
physician. If the pharmacist was also selecting and ordering a pharmacogenomic test, the PCPs
find this to be more appropriate when the pharmacist was located in the clinic as well, as
opposed to being in the community. This IAM score was nearly identical to the average score
when the physician was responsible for selecting and ordering with a pharmacist in the clinic.
These results seem to indicate that the physical presence of a pharmacist is driving physician
perceptions of how appropriate delivery of clinical pharmacogenomics is to their primary care
practice.
Regarding the feasibility outcome, when the pharmacist was responsible for managing
results and modifying drug therapy, PCPs found this to be more feasible when the pharmacist
was located in the clinic. Interestingly, the “pharmacist in the clinic” cell mean differences were
identical for this interaction term on both the IAM and FIM scales, with similar overall mean
scores. The absence of significance for feasibility may be due to a smaller cell mean difference in
the “in the community” scenario. However, it is important to note the similarities between the
scores for the appropriateness and feasibility of delivering pharmacogenomics when a
pharmacist is physically located in the clinic and is responsible for managing and modifying the
drug regimen. Additional investigations of this potential relationship would be needed to confirm
this trend.
137

Results from this study indicate that physicians may be willing to sacrifice some clinical
decision-making autonomy when dealing with the delivering of pharmacogenomics. The positive
results regarding appropriateness of an in-clinic pharmacist handling the management of test
results and modification of drug therapy is particularly illuminating. The responsibility of
modifying drug therapy is currently the highest levels of clinical practice a pharmacist is allowed
to engage in under a CPA.25,26 These results may be indicative of a larger theme in the literature
that primary care physicians lack understanding of pharmacogenomics and may be willing to
defer to pharmacists if physical oversight remains possible.7
Additional results from the study may provide evidence for why physicians were willing
to relinquish some autonomy for the delivery of clinical pharmacogenomics. Results on the “Preimplementation Provider” items from the IGNITE Spark Toolbox all hovered around the midpoint on the agree/disagree Likert-type item. Scores on the general familiarity with
pharmacogenomic question were somewhat lower than the IGNITE items, but more interesting
was the drastically lower scores regarding primary care physician familiarity with CPIC and
PharmaGKB. More research should be done to reveal where physicians are currently getting this
type of information from if not CPIC or PharmGKB, and what can be done to increase awareness
and use of these resources.
The results from the three regression models revealed several strong predictors of scores
on the baseline assessment of the AIM, IAM, and FIM scales. The reported importance of
collaborating with a pharmacist and perceived PGx knowledge demonstrated a stronger effect on
the dependent variable than the familiarity with PGx resources. This positive relationship
between pharmacist collaboration and scores on the acceptability, appropriateness, and feasibility
of clinical pharmacogenomics seems to be in line with the findings from the vignettes. Although
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we did not have significant main effects in that analysis, these additional regression results, taken
together with the interactions noted previously, show that physicians value the contribution of a
pharmacist when delivering clinical pharmacogenomics in primary care.
The findings from this current study are also consistent with the previous work that is
available. The two-arm pilot study discussed earlier reported a significantly higher number of
pharmacogenomic tests ordered when a pharmacist was located in-house, as well as an increase
in the number of pharmacist consultations.34 The pre-pilot survey found that most physicians
already believed either pharmacists or geneticists/genetic counselors were likely to have a role in
this clinical delivery.34 Others have proposed that these two types of non-physician providers can
play complementary roles in the effective delivery of pharmacogenomics.23,44
It is important to consider the implications of this study in light of how prepared the
pharmacist is to take on these additional responsibilities. Pharmacists have generally positive
attitudes toward their role in delivering pharmacogenomics, have been instrumental in the
development of research-based implementations of clinical pharmacogenomics in the US and
abroad, and are continuing to lead efforts in clinical education of pharmacogenomics.13,17,19 Also,
ongoing research is contributing to our understanding of how feasible it is for pharmacists to be
the ones delivering this information.45-47 These studies show that pharmacists are making correct
interpretations of test results close to 90% of the time, consultations were timely and patients
understand the information, as well as there being high rates of adherence to pharmacist
recommendations by patients.
There remains limited literature available addressing the issue of physician-pharmacist
collaboration in primary care specific to clinical pharmacogenomics. However, this is of great
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importance as patients are becoming increasing interested and aware of genomic testing and
pharmacogenomics.48 An in-depth qualitative assessment of patient perceptions to genomic
testing revealed that patients believe that pharmacogenomics could be helpful in identifying
problematic prescriptions and used to inform future prescribing.48 However, concerns around
insurance coverage and who should have access to the information were noted. While patients
felt the pharmacist could effectively use the pharmacogenomic data, some thought this
interaction was redundant while others rely solely on their physician for medication
information.49
The findings of this current study support the idea that pharmacists co-located with
physicians may be effective collaborators in the delivery of clinical pharmacogenomics and
extend our understanding of how appropriate and feasible this scenario is to primary care
physicians.
Limitations
This study was hypothetical in nature and asked physicians to imagine themselves
essentially engaged in a collaborative practice agreement with a pharmacist. Since familiarity
with collaborative practice agreements was relatively low and few respondents were engaged in
such an arrangement, external validity of the relationships shown herein should be externally
validated in future studies with non-collaborative control groups. About half of the responding
physicians had never ordered a pharmacogenomic test and may have also biased the responses.
Another limitation in our manipulation may stem from the fact that we did not perform any
manipulation checks on the manipulations themselves. This could have led to poor manipulation
performance and thus the loss of an effect that may have otherwise been there. However, the
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manipulations were piloted with two primary care physicians before distribution. Their
comments indicated that they understood the differences in the various scenarios.
Conclusion
When a pharmacist is responsible for managing and modifying drug therapy based on
pharmacogenomic results, primary care physicians find this more appropriate for their practice
when the pharmacist is located in the clinic. Physicians also responded that this same scenario
would likely be more feasible. There is also evidence that it is more appropriate for the
pharmacist to be located in the clinic if they are also responsible for selecting and ordering a
pharmacogenomic test.
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APPENDIX 1. – SURVEY INSTRUMENT
Welcome and thank you! You are being asked to volunteer for this research study. It is up to you
whether you choose to participate or not. There will be no penalty or loss of benefits to which
you are otherwise entitled if you choose not to participate or discontinue participation. You will
be required to answer each question. As a reminder, this study has been IRB approved and we do
not believe there are any risks associated with this survey.
By now you will have read both the invitation email and the information above. By continuing to
the next page you verify that you are at least 18 years of age and give your consent to participate
in this study.
NEXT PAGE
Part A. Practice and Other Characteristics
The questions in this section will help us better understand you and your current medical
practice.
1. What is your primary medical specialty (i.e., the practice specialty where you spend the
most hours per week)?
A. Family Medicine
B. General Internal Medicine
C. Pediatrics
D. Psychiatry
E. Other
IF C, D, or E SELECTED IN Q1, THEN END SURVEY
2. Are you currently licensed and actively practicing in this specialty?
A. Yes
B. No
IF B SELECTED IN Q2, THEN END SURVEY
3. What percent of your time is spent in the following activities?
A. Direct outpatient care _______ % (IF LESS THAN 25%, END SURVEY)
B. Hospital inpatient care _______ % (IF MORE THAN 50%, END SURVEY)
C. Administrative activities, teaching, or research _______ % (IF MORE THAN
50%, END SURVEY)
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IF THE RESPONDENT HAS SATISFACTORILY ANSWERED THE PREVIOUS THREE
QUESTIONS, THEY ARE ELIGIBLE FOR THE FULL SURVEY

4. In what state do you primarily practice?
_________________
CAPTURE AT LEAST 20 PEOPLE FROM EACH REGION BELOW IN Q4
Midwest (Ohio, Indiana, Michigan, Illinois, Missouri, Wisconsin, Minnesota, Iowa, Kansas, Nebraska, South
Dakota, North Dakota)

Northeast (Maine, Massachusetts, Rhode Island, Connecticut, New Hampshire, Vermont, New York,
Pennsylvania, New Jersey, Delaware, Maryland)

Southeast (West Virginia, Virginia, Kentucky, Tennessee, North Carolina, South Carolina, Georgia, Alabama,
Mississippi, Arkansas, Louisiana, Florida)

Southwest (Texas, Oklahoma, New Mexico, Arizona)
West (Colorado, Wyoming, Montana, Idaho, Washington, Oregon, Utah, Nevada, California, Alaska, Hawaii)

5. How many years have you been in practice since finishing your residency?
A. Less than 5
B. 5 – 15
C. 16 – 25
D. More than 25
6. Which of the following most closely represents your current professional status?
A. Practice owner/partner/associate
B. Employed by a hospital or health system
C. Employed by a medical group
D. Employed by a university hospital or health system
E. Other
7. Is your practice:
A. Solo
B. 2 – 5 physicians
C. 6 – 10 physicians
D. 11 – 30 physicians
E. 31 – 100 physicians
F. 101 or more physicians
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8. How many physicians, including you, work in your main primary care practice location
(the location where you spend most of your time during the week)?
__________________ physicians
9. Is your primary care practice located in a single specialty or multi-specialty practice?
(multi-specialty practice includes physician specialists other than primary care)
A. Single specialty
B. Multi-specialty
10. What percentage of your practice is staffed by non-physician advanced practice
providers? (e.g. nurse practitioners and physician assistants)
________________%

11. On average, what is your best estimate for the number of patients you see per day in your
primary care practice?
___________________ patients
12. Which of the following options best describes pharmacist involvement with your primary
care practice?
A. Full-time staff pharmacist that works in your primary care practice
B. Part-time staff or consultant pharmacist that works in your primary care practice
C. I only have interactions with community pharmacists not employed in my primary
care practice (i.e., independent, chain, retail, grocery-store pharmacies)
D. Other; please describe _____________________________
13. How important, to you, is collaborating with a pharmacist for the care of patients in your
primary care practice?
Not at all
important

Slightly
important

Somewhat
important

Moderately
important

Extremely
important

1

2

3

4

5

14. Please rate your level of familiarity with formal collaborative practice agreements
between physicians and pharmacists.
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Not at all
familiar

Slightly
familiar

Somewhat
familiar

Moderately
familiar

Extremely
familiar

1

2

3

4

5

SHOW THIS STATEMENT TO ALL RESPONDENTS AFTER Q14.
❖ Collaborative practice agreements (CPAs) are used to create formal relationships between
pharmacists and physicians, or other providers. This allows the pharmacist to provide
expanded clinical services to patients and the healthcare team.
❖ CPAs define certain patient care functions that a pharmacist can autonomously provide
under specified situations and conditions. Of important note, CPAs are not required for
pharmacists to perform many patient care services (e.g., medication reviews, patient
education and counseling, disease screening).
❖ A CPA allows qualified pharmacists to assume professional responsibility for performing
patient assessments and making referrals, ordering and reviewing laboratory tests,
administering medications, and selecting, initiating, monitoring, continuing, and
adjusting medication regimens.
❖ References – (https://www.aphafoundation.org/collaborative-practice-agreements,
https://www.cdc.gov/dhdsp/pubs/guides/best-practices/pharmacist-cdtm.htm)
15. Is pharmacist involvement in your primary care practice part of a collaborative practice
agreement (CPA)?
A. Yes
B. No
C. Not sure
IF A SELECTED IN Q15, SHOW Q16
16. What level of access do pharmacists have to patient medical records in your main
primary care practice location?
A. Full access
B. Limited access (e.g., only medication related information)
C. No access
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Part B. Clinical pharmacogenomics
The questions in this section will help us better understand your experience with and
perspectives on clinical pharmacogenomics.
17. Please rate your familiarity with using clinical pharmacogenomic information.
Not at all
familiar

Slightly
familiar

Somewhat
familiar

Moderately
familiar

Extremely
familiar

1

2

3

4

5

SHOW THIS STATEMENT TO ALL RESPONDENTS AFTER Q15.
❖ Clinical pharmacogenomics is the application of pharmacogenomics, a field of medicine
that studies how individual genetic differences may govern drug toxicity and/or response,
for use in clinical practice.
❖ Pharmacogenomics can be classified as either germline pharmacogenomics, which refers
to the study of how inherited genomic variants influence alterations in a medication’s
pharmacokinetic and pharmacodynamic properties, or somatic pharmacogenomics, which
studies how acquired genomic variants influence medication response (e.g. cancers and
infectious disease).
❖ Diagnostic testing to identify these genomic variants includes single-gene testing, multigene panel testing, and sequencing. This can be done either reactively, ordering a test
when a patient is likely to be prescribed a drug with pharmacogenomic implications, or
preemptively, independent of whether the patient is receiving a medication or not.
❖ References – Borden et al., Pharmacogenomics J 2019, Relling and Evans, Nature 2015.
Please rate your level of agreement with the following statements.
18. Clinical pharmacogenomics meets my approval
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5
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19. Clinical pharmacogenomics is appealing to me
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

20. I like clinical pharmacogenomics
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

21. I welcome clinical pharmacogenomics
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

Please rate your level of agreement with the following statements.
22. Clinical pharmacogenomics seems fitting in my primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

23. Clinical pharmacogenomics seems suitable for my primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5
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24. Clinical pharmacogenomics seems applicable to my primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

25. Clinical pharmacogenomics seems like a good match for my primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

Please rate your level of agreement with the following statements.
26. Clinical pharmacogenomics seems implementable in my primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

27. Clinical pharmacogenomics seems possible for my primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

28. Clinical pharmacogenomics seems doable in my primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5
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29. Clinical pharmacogenomics seems easy to use at primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

Please read the following scenario carefully and answer the questions that follow based on
the scenario.
RESPONDENTS SHOWN ONLY ONE VIGNETTE – EQUAL QUOTA PER VIGNETTE
Vignette #1 - You have a collaborative practice agreement with a clinical pharmacist who works
in your primary care clinic. This pharmacist operates under a defined protocol that allows them
to work autonomously at higher levels of clinical practice. In addition to their medication therapy
management duties, this pharmacist may initiate, continue, modify, or discontinue medications,
order and review laboratory tests, and make referrals to other medical providers.
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in
your primary care clinic would look like this.

▪ The collaborative practice clinical pharmacist provides services while being
physically located in your primary care clinic.

▪ This clinical pharmacist is responsible for selecting and ordering the
pharmacogenomic test for the patient.
▪ The clinical pharmacist manages the return of results and prepares a report for the
patient’s medical record. The report includes the results and the potential implications
on all relevant medication therapy.
▪ The clinical pharmacist is also responsible for making any appropriate modifications
to the patient’s medication regimen considering the pharmacogenomic information
now available.
Vignette #2 - You have a collaborative practice agreement with a local pharmacy that provides
pharmacogenomic services. The clinical pharmacists operate under a defined protocol that allows
them to work autonomously at higher levels of clinical practice. In addition to their medication
therapy management duties, these pharmacists may initiate, continue, modify, or discontinue
medications, order and review laboratory tests, and make referrals to other medical providers.
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in
your primary care clinic would look like this.
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▪ The collaborative practice clinical pharmacist provides services while not being
physically located in your primary care clinic.
▪ This clinical pharmacist is responsible for selecting and ordering the
pharmacogenomic test for the patient.
▪ The clinical pharmacist manages the return of results and prepares a report for the
patient’s medical record. The report includes the results and the potential implications
on all relevant medication therapy.
▪ The clinical pharmacist is also responsible for making any appropriate modifications
to the patient’s medication regimen considering the pharmacogenomic information
now available.
Vignette #3 - You have a collaborative practice agreement with a clinical pharmacist who works
in your primary care clinic. This pharmacist operates under a defined protocol that allows them
to work autonomously at higher levels of clinical practice. In addition to their medication therapy
management duties, this pharmacist may initiate, continue, modify, or discontinue medications,
and make referrals to other medical providers.
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in
your primary care clinic would look like this.

▪ The collaborative practice clinical pharmacist provides services while being
physically located in your primary care clinic.
▪ You, the physician, are responsible for selecting and ordering the pharmacogenomic
test for the patient.
▪ The clinical pharmacist manages the return of results and prepares a report for the
patient’s medical record. The report includes the results and the potential implications
on all relevant medication therapy.
▪ The clinical pharmacist is also responsible for making any appropriate modifications
to the patient’s medication regimen considering the pharmacogenomic information
now available.
Vignette #4 - You have a collaborative practice agreement with a local pharmacy that provides
pharmacogenomic services. The clinical pharmacists here operate under a defined protocol that
allows them to work autonomously at higher levels of clinical practice. In addition to their
medication therapy management duties, these pharmacists may initiate, continue, modify, or
discontinue medications, and make referrals to other medical providers.
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in
your primary care clinic would look like this.

▪ The collaborative practice clinical pharmacist provides services while not being
physically located in your primary care clinic.
▪ You, the physician, are responsible for selecting and ordering the pharmacogenomic
test for the patient.
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▪ The clinical pharmacist manages the return of results and prepares a report for the
patient’s medical record. The report includes the results and the potential implications
on all relevant medication therapy.
▪ The clinical pharmacist is also responsible for making any appropriate modifications
to the patient’s medication regimen considering the pharmacogenomic information
now available.
Vignette #5 - You have a collaborative practice agreement with a clinical pharmacist who works
in your primary care clinic. This pharmacist operates under a defined protocol that allows them
to work autonomously at higher levels of clinical practice. In addition to their medication therapy
management duties, this pharmacist may order and review laboratory tests, and make referrals to
other medical providers.
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in
your primary care clinic would look like this.

▪ The collaborative practice clinical pharmacist provides services while being
physically located in your primary care clinic.
▪ The clinical pharmacist is responsible for selecting and ordering the
pharmacogenomic test for the patient.
▪ You, the physician, manage the return of results and prepare a report for the patient’s
medical record. The report includes the results and the potential implications on all
relevant medication therapy.
▪ You are also responsible for making any appropriate modifications to the patient’s
medication regimen considering the pharmacogenomic information now available.
Vignette #6 - You have a collaborative practice agreement with a local pharmacy that provides
pharmacogenomic services. The clinical pharmacists here operate under a defined protocol that
allows them to work autonomously at higher levels of clinical practice. In addition to their
medication therapy management duties, these pharmacists may order and review laboratory tests,
and make referrals to other medical providers.
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in
your primary care clinic would look like this.

▪ The collaborative practice clinical pharmacist provides services while not being
physically located in your primary care clinic.

▪ The clinical pharmacist is responsible for selecting and ordering the
pharmacogenomic test for the patient.
▪ You, the physician, manage the return of results and prepare a report for the patient’s
medical record. The report includes the results and the potential implications on all
relevant medication therapy.
▪ You are also responsible for making any appropriate modifications to the patient’s
medication regimen considering the pharmacogenomic information now available.
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Vignette #7 - You have a collaborative practice agreement with a clinical pharmacist who works
in your primary care clinic during the week. This pharmacist operates under a defined protocol
that allows them to work autonomously at higher levels of clinical practice. In addition to their
medication therapy management duties, this pharmacist may make referrals to other medical
providers.
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in
your primary care clinic would look like this.

▪ The collaborative practice clinical pharmacist provides services while being
physically located in your primary care clinic.
▪ You, the physician, are responsible for selecting and ordering the pharmacogenomic
test for the patient.
▪ You manage the return of results and prepare a report for the patient’s medical record.
The report includes the results and the potential implications on all relevant
medication therapy.
▪ You are also responsible for making any appropriate modifications to the patient’s
medication regimen considering the pharmacogenomic information now available.
Vignette #8 - You have a collaborative practice agreement with a local pharmacy that provides
pharmacogenomic services. The clinical pharmacists here operate under a defined protocol that
allows them to work autonomously at higher levels of clinical practice. In addition to their
medication therapy management duties, these pharmacists may make referrals to other medical
providers.
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in
your primary care clinic would look like this.

▪ The collaborative practice clinical pharmacist provides services while not being
physically located in your primary care clinic.
▪ You, the physician, are responsible for selecting and ordering the pharmacogenomic
test for the patient.
▪ You manage the return of results and prepare a report for the patient’s medical record.
The report includes the results and the potential implications on all relevant
medication therapy.
▪ You are also responsible for making any appropriate modifications to the patient’s
medication regimen considering the pharmacogenomic information now available.
Please rate your level of agreement with the following statements based on the previous
scenario.
30. Clinical pharmacogenomics delivered this way seems fitting in my primary care practice
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Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

31. Clinical pharmacogenomics delivered this way seems suitable for my primary care
practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

32. Clinical pharmacogenomics delivered this way seems applicable to my primary care
practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

33. Clinical pharmacogenomics delivered this way seems like a good match for my primary
care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5
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Please rate your level of agreement with the following statements based on the previous
scenario.
34. Clinical pharmacogenomics delivered this way seems implementable in my primary care
practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

35. Clinical pharmacogenomics delivered this way seems possible for my primary care
practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

36. Clinical pharmacogenomics delivered this way seems doable in my primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

37. Clinical pharmacogenomics delivered this way seems easy to use at primary care practice
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

For the remaining questions, you do not need to consider the information presented in the
previous scenario.
38. In your opinion, what is biggest barrier to more widespread use of clinical
pharmacogenomics in your primary care practice?
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A.
B.
C.
D.
E.

Physician education in the appropriate use of pharmacogenomics
Patient interest and engagement
Insurance coverage and affordability
Evidence base to support routine use of pharmacogenomics
Electronic health record tools for pharmacogenomics

39. If prescribing and ordering a pharmacogenomic test were not part of your clinical
workflow, and the information was readily available in your patient’s medical record at
the point of prescribing, would this make the delivery of clinical pharmacogenomics
more feasible?
A. Yes
B. No
40. On average, how often do patients ask you about pharmacogenomic testing?
a) Every week
b) Every month
c) Every 6 months
d) I have never been asked about pharmacogenomic testing by a patient
41. On average, how often do you use pharmacogenomic information in the care of specific
patients?
a) Every week
b) Every month
c) Every 6 months
d) I have never used pharmacogenomic information

Please rate your level of agreement with the following statements:
42. I am confident in my ability to use the results of a pharmacogenomic test.
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5
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43. My training has prepared me to treat patients whose genetics place them at high risk for
medical conditions.
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

44. I can find/use reliable sources of the information I need to apply pharmacogenomic
testing while caring for patients
Strongly
disagree

Tend to
disagree

Neither agree
nor disagree

Tend to agree

Strongly agree

1

2

3

4

5

Please rate your level of familiarity with the following pharmacogenomic resources.
45. CPIC – The Clinical Pharmacogenetics Implementation Consortium
Not at all
familiar

Slightly
familiar

Somewhat
familiar

Moderately
familiar

Extremely
familiar

1

2

3

4

5

46. PharmGKB – Pharmacogenomics Knowledgebase
Not at all
familiar

Slightly
familiar

Somewhat
familiar

Moderately
familiar

Extremely
familiar

1

2

3

4

5
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APPENDIX 2. SUMMARY OF RESULTS PROVIDED TO RESPONDING
PHYSICIANS
TITLE: Sustainable Delivery of Pharmacogenomics in Primary Care: Testing the Potential for
Physician-Pharmacist Collaboration
PURPOSE
Advancement in the clinical implementation of pharmacogenomics can be largely attributed to
numerous large-scale academic research programs over the past decade. Most of these programs
utilize a transdisciplinary model of physician-pharmacist collaboration for delivering
pharmacogenomics. Drawing from literature showing improved outcomes from such
collaborations, the successes of ongoing implementation programs, and theoretical work from
the field of implementation science, this study sets out to experimentally test this collaboration in
the primary care setting.
METHODS
This study utilized a 2x2x2 between-subjects experimental design with data collected using an
online survey and hypothetical vignettes. Responses were received from 176 US-based primary
care physicians (PCPs). Primary outcome measures: Intervention Appropriateness Measure
(IAM) and Feasibility of Intervention Measure (FIM). Manipulated vignette factors: location of
the pharmacist (in clinic vs. not), who selects and orders the test (pharmacist vs. physician), and
who manages and modifies the medication regimen (pharmacist vs. physician).
RESULTS
The main effects on the IAM were not statistically significant at α <0.05. However, the two-way
interaction effect between location and who manages and modifies the medication regimen was
statistically significant (p=0.04). Although not statistically significant, a second potential
crossover interaction effect was observed between location and who selects and orders the test
(p=0.09). Results of the manipulations on the FIM scale showed no significance of the main
effects or interactions, but a non-significant crossover interaction was observed between location
and who manages and modifies the medication regimen (p=0.09).
CONCLUSIONS
PCPs find the delivery of pharmacogenomics significantly more appropriate for their practice
when the pharmacist is managing and modifying the patient’s medication regimen while located
in the clinic. PCPs responded that this same scenario would likely be more feasible. There is also
evidence that it is more appropriate for the pharmacist to select and order the test when located in
the clinic.
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General Practice Characteristics

Frequency (%)

Primary medical specialty
Family Medicine

111 (63%)

Internal Medicine

65 (37%)

Region
Midwest

50 (28%)

West

31 (18%)

Southwest

20 (11%)

Northeast

33 (19%)

Southeast

42 (24%)

Years in practice
4 (2%)

Less than 5
5 – 15

20 (11%)

16 – 25

68 (39%)

More than 25

84 (48%)

Professional status
Practice owner/partner/associate

91 (52%)

Employed by hospital or health system

43 (24%)

Employed by medical group

31 (18%)

Employed by a university hospital or health system

9 (5%)

Other

2 (1%)

Size of practice (# of physicians)
Solo
2–5

43 (24%)
58 (33%)

6 – 10

25 (14%)

11 – 30

18 (10%)

31 – 100

16 (9%)

More than 100

16 (9%)

Single or multi-specialty clinic
Single specialty

119 (68%)

Multi-specialty

57 (32%)
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Pharmacist related practice characteristics

Mean

Importance of collaborating with pharmacist for care of patients in the
primary care practice
(1 = Not at all important, 5 = Very important)

3.47

Familiarity with CPAs between physicians and pharmacists
(1 = Not at all familiar, 5 = Very familiar)

2.50
Frequency (%)

Pharmacist involvement in practice
Full-time staff that works in the clinic

23 (13%)

Part-time staff or consultant that works in the clinic

16 (9%)

Only interacts with community pharmacist not employed by practice

134 (76%)

Pharmacist involvement is part of a CPA
Yes

27 (15%)

No

124 (70%)

Not sure

25 (14%)

Level of CPA pharmacist access to patient medical records (n=27)
Full access

23 (85%)

Limited access (e.g. only medication related information)

4 (15%)

Mean

Pharmacogenomics familiarity
(1 = Not at all familiar, 5 = Very familiar)
Familiarity with using clinical pharmacogenomic information

2.63

Familiarity with CPIC

1.61

Familiarity with PharmGKB

1.59

Pre-implementation Provider Items from IGNITE Spark Toolbox
(1 = Strongly disagree, 5 = strongly agree)
“I am confident in my ability to use the results of a pharmacogenomic
test”

3.18

“My training has prepared me to treat patients whose genetics place them
at a high risk for medical conditions”

2.96

“I can find/use reliable sources of the information I need to apply
pharmacogenomic testing while caring for patients”

3.18

Use of pharmacogenomics in practice

Frequency (%)
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Frequency with which patients ask PCP about pharmacogenomic testing
Every week
Every month
Every six months
Never been asked about it

6 (3%)
20 (11%)
34 (19%)
116 (66%)

Frequency with which PCPs use pharmacogenomic information in the
care of specific patients
Every week
Every month
Every six months
Never been asked about it

11 (6%)
29 (16%)
40 (23%)
96 (55%)

Biggest barrier to more widespread use of pharmacogenomics in their
primary care practice
Physicians knowledge regarding appropriate use
Patient interest and engagement

33 (19%)
11 (6%)

Insurance coverage and affordability

93 (53%)

Evidence base to support routine use of pharmacogenomics

34 (19%

Electronic health record tools for pharmacogenomics

5 (3%)

Pharmacogenomics more feasible if prescribing and orderings were not
part of clinical workflow, and information was already in medical record
Yes
No

143 (81%)
33 (19%)

Implementation Outcome Measures Applied to Clinical
Pharmacogenomics
(1 = Strongly disagree, 5 = Strongly Agree)

Mean (SD)

Acceptability of Intervention Measure (AIM)
Clinical pharmacogenomics meets my approval

3.72

Clinical pharmacogenomics is appealing to me

3.77

I like clinical pharmacogenomics

3.62

I welcome clinical pharmacogenomics

3.73
Overall Mean = 3.71

Intervention Appropriateness Measure (IAM)
Clinical pharmacogenomics seems fitting in my primary care practice
Clinical pharmacogenomics seems suitable for my primary care practice
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3.45
3.48

Clinical pharmacogenomics seems applicable to my primary care practice

3.60

Clinical pharmacogenomics seems like a good match for my primary care
practice

3.49
Overall Mean = 3.50

Feasibility of Intervention Measure (FIM)
Clinical pharmacogenomics seems implementable in my primary care
practice

3.19

Clinical pharmacogenomics seems possible for my primary care practice

3.54

Clinical pharmacogenomics seems doable in my primary care practice

3.36

Clinical pharmacogenomics seems easy to use at my primary care practice

2.99

Overall Mean = 3.27
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APPENDIX 3. DEMOGRAPHIC AND PRACTICE CHARACTERISTICS
General Practice Characteristics

Percentage of respondents

Primary medical specialty
Family Medicine

63%

Internal Medicine

37%

Region
Midwest

28%

West

18%

Southwest

11%

Northeast

19%

Southeast

24%

Years in practice
Less than 5

2%

5 – 15

11%

16 – 25

39%

More than 25

48%

Professional status
Practice owner/partner/associate

52%

Employed by hospital or health system

24%

Employed by medical group

18%

Employed by a university hospital or health system

5%

Other

1%

Size of practice (# of physicians)
Solo
2–5

24%
33%

6 – 10

14%

11 – 30

10%

31 – 100

9%

More than 100

9%

Single or multi-specialty clinic
Single specialty

68%

Multi-specialty

32%

Table 1. Practice characteristics among all respondents
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Pharmacist related practice characteristics

Mean

Importance of collaborating with pharmacist for care of patients in the
primary care practice
(1 = Not at all important, 5 = Very important)

3.47

Familiarity with CPAs between physicians and pharmacists
(1 = Not at all familiar, 5 = Very familiar)

2.50
Percentage of
respondents

Pharmacist involvement in practice
Full-time staff that works in the clinic

13%

Part-time staff or consultant that works in the clinic

9%

Only interacts with community pharmacist not employed by practice

76%

Pharmacist involvement is part of a CPA
Yes

15%

No

70%

Not sure

14%

Level of CPA pharmacist access to patient medical records (n=27)
Full access

85%

Limited access (e.g. only medication related information)

15%

Table 2. Pharmacist related practice characteristics among all respondents
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Pharmacogenomics related questions
Pharmacogenomics familiarity
(1 = Not at all familiar, 5 = Very familiar)

Mean

Familiarity with using clinical pharmacogenomic information

2.63

Familiarity with CPIC

1.61

Familiarity with PharmGKB

1.59

Pre-implementation Provider Items from IGNITE Spark Toolbox
(1 = Strongly disagree, 5 = strongly agree)
“I am confident in my ability to use the results of a pharmacogenomic
test”

3.18

“My training has prepared me to treat patients whose genetics place them
at a high risk for medical conditions”

2.96

“I can find/use reliable sources of the information I need to apply
pharmacogenomic testing while caring for patients”

3.18
Percentage of
respondents

Use of pharmacogenomics in practice
Frequency with which patients ask PCP about pharmacogenomic testing
Every week
Every month
Every six months
Never been asked about it

3%
11%
19%
66%

Frequency with which PCPs use pharmacogenomic information in the
care of specific patients
Every week
Every month
Every six months
Never used it

6%
16%
23%
55%

Biggest barrier to more widespread use of pharmacogenomics in their
primary care practice
Physicians knowledge regarding appropriate use
Patient interest and engagement

19%
6%

Insurance coverage and affordability

53%

Evidence base to support routine use of pharmacogenomics

19%

Electronic health record tools for pharmacogenomics
Pharmacogenomics more feasible if prescribing and ordering were not
part of clinical workflow
Yes
No
Table 3. Pharmacogenomic related practice characteristics across all respondents
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3%

81%
19%

CONCLUSION
We have designed and completed three complementary research studies focused on the
clinical implementation of pharmacogenomic testing and the factors contributing to the
sustainability of the science within its current environment and its sustainability in future
settings. Theory guiding this work has been taken from the discipline of implementation science
and one of its foundational concepts, sustainability. Public health organizations in the US
including the Centers for Disease Control and Prevention (CDC) and the National Institutes of
Health (NIH) have been leading this call.1,2 The National Cancer Institute (NCI) at the NIH has
been particularly strong in its advocacy of implementation science more generally and not just in
genomics.3 The issue of translating evidence-based research into clinical application reaches all
corners of medicine, including pharmacogenomics, and thus the more formal integration of
implementation science principles is warranted. These three studies will also continue building
the ongoing relationship between implementation science and genomic medicine. Additionally,
the two primary data collection studies are the first to formally apply an implementation science
framework or implementation science outcomes to the field of pharmacogenomics.
The scoping review study began this three-part work with an examination of the extent to
which previous research has explicitly assessed health care provider interactions with and use of
pharmacogenomics in hypothetical or real-world practice. While this study did not apply a
certain implementation science framework, as in the qualitative piece, the Dynamic
Sustainability Framework (DSF) provides the reader with a reflection on the importance of field
conducting such studies. In the introduction we mentioned two tenets of the DSF: “interventions
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can be continually improved, specific to each setting” and “ongoing feedback is essential and
should be measured over time”.4 These thoughts helped tighten our research question to make
this study unique and an important contribution to the literature. The literature has seen a great
deal of work targeted to understand the perceptions and opinions of providers toward the use of
pharmacogenomics, however cross-sectional studies of this nature miss the mark when we look
at those two tenets of the DSF.5-8 It is methodologies found in the studies included in the scoping
review that position implementers to be able to continually improve and assess feedback from
the actual experience using a new intervention such as pharmacogenomic testing.
Most of the 25 studies included in our scoping review were published between 2015 and
2018 on the North American and European continents. This was over double the number of
studies published the previous five-year block (2010-2014) and demonstrates a promising trend
that researchers and implementers are recognizing the importance of such methodologies. It
would be intriguing to compare these results with the publication trends of studies that only
assess perceptions or opinions regarding pharmacogenomics. We found that the largest number
of included studies were those using hypothetical clinical case scenarios closely followed by
real-world studies regarding prescribing and testing decisions. Many of these studies were
focused on evaluating the clinical decision support (CDS) systems that enable providers to
deliver timely and clinically relevant pharmacogenomic information to patients.9 While
understanding how providers interacted with these systems was important, several studies also
aimed to measure the adherence or compliance physicians had to the recommendations of their
human colleagues, pharmacists, regarding medication use in light of genomic information. In
only one study was the pharmacist the primary respondent for data collection, but in many in
they were responsible for the clinical action the physician was acting on.10 In fact, some of the
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more robustly designed studies were those with the pharmacists at the center of the research
question.10,11 The discussion over who should be responsible for managing pharmacogenomic
results and delivery of information to the patient is ongoing.
The choice to focus on methodology in this review was appropriate for the field
currently. As researchers look to answer questions about the best way to deliver
pharmacogenomic CDS or which provider is best for delivery this information to patients, the
illuminating findings from this study should give future researchers a firm and broad baseline
assessment of methodologies to carry forward and build upon. Understanding the methods of
current researchers and implementers and their historical applications will hopefully create a
sustainable future for clinical pharmacogenomics.
The second research study herein was the most explicit of the three in its use of
implementation science to guide the research design and data collection. Researchers in the
IGNITE group have led the way with their previous research on genomic medicine and
implementation science.12,13 The work of the Common Measures working group was
instrumental in the decision to pursue a focus on the Process domain. Further, the application of
the Process domain was strengthened by the identification of several highly ranked constructs of
importance to the sustainability of genomic medicine. The connection between the foundational
concept of sustainability and the Process domain is underpinned by the operational indicator of
sustainability, capacity building. Previous research conceptualized this not only as a physical
indicator, but human as well.14 The constructs and sub-constructs of the Process domain use
almost identical language as some of the factors represented by these physical and human
infrastructures in previous literature.15,16
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The findings from this study demonstrated a strong focus throughout on effective
communication as a facilitator of success across many of the constructs and sub-constructs. The
Planning construct involved numerous discussions on the need to understand the existing interest
and testing volume prior to implementing. This was a crucial factor for many as it determined a
first gene-drug pair implementation target and the desire to get an “early-win” for their program.
The Engaging construct, more than any other construct, dealt with the human capacity building
indicator of sustainability. Cutting across several types of essential personnel, this construct
provided more nuance on the influence certain individuals or types of individuals had on
colleagues and the success of the program. The importance of quick, frequent, and informal
interactions with providers cannot be understated. This was one of the most ubiquitous findings
in the whole study. The Reflecting & Evaluating construct showed that the goals of most of this
early adopter programs was simply to provide pharmacogenomics to the patients. Patient safety
was cited several times a primary driver of this goal. Outcomes based studies are planned in the
future for many of the participant institution, but at this time process metrics and structured
provider feedback make up most data collection.
This research represents one the first formal applications of an implementation science
framework to the study of clinical pharmacogenomics. Further, we have tied the formal use of
such a framework to the one of its discipline’s foundational concepts, sustainability, and the
identified constructs necessary to achieve that in genomic medicine. As evidenced herein by the
ongoing challenges among pioneers in the implementation of pharmacogenomics, sustainability
is not just an economic construct related to coverage and reimbursement policies. Successfully
sustaining pharmacogenomics within participant institutions and designing future
implementations with a mindset of sustainability will require precision targeting of supportive
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administration and clinicians, maintaining dedicated IT support throughout, and remaining
resilient in the face of inevitable failures.
The final study of this three-part work explored more deeply the topic that we have
already discussed in each of the two previous studies. That is, the question of which health care
providers are best positioned to deliver care using pharmacogenomic information. The scoping
review included one study that investigated whether specialists or primary care providers should
carry this responsibility, but the larger discussion has centered on what level of involvement the
pharmacist should have in conducting pharmacogenomic testing and the interpretation of
results.11,17,18 Pharmacist involvement to date in the implementation of clinical
pharmacogenomic programs at major academic institutions has been robust. However, there has
been little investigation into how the pharmacist’s skill set can be utilized in a primary care
setting and what is the attitude of primary care physicians towards their use.19,20 To understand
this more fully, we applied three validated implementation science outcome measures
(acceptability, appropriateness, feasibility) that were created to enable more standardized
assessments of conceptualizing and evaluating the success of an intervention.21,22
Results from our cross-sectional survey indicated that primary care physicians were
accepting of pharmacogenomics but the feasibility of delivering it in their practice produced
somewhat lower scores. Using an experimental vignette methodology, in the second portion of
the survey we explored the appropriateness and feasibility of delivering pharmacogenomics in a
collaborative practice agreement across different levels of pharmacist responsibility. We tested
three main effects: location of the pharmacist (in or out of the clinic), provider responsible for
selecting and ordering the test (pharmacist or physician), and the provider responsible for
managing results and modifying drug therapy (pharmacist or physician). When the pharmacist
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was responsible for managing pharmacogenomic results and modifying drug therapy, primary
care physicians found this to be more appropriate when the pharmacist was physically located in
the clinic. Also, although not statistically significant at α=0.05, the same scenario just described
was seen as more feasible according to our sample of primary care physicians. Lastly, when the
pharmacist was located in the clinic, physicians were indifferent regarding the appropriateness of
themselves or the pharmacist selecting and ordering the pharmacogenomic test.
This study builds on previous pilot work that tested the effects of pharmacist integration
into a primary care practice on testing volume and utilization of pharmacist consult.11 However,
we have produced results with broader generalizability because the investigation was not
restricted to one geographic set of primary care practices. These results clearly show that primary
care physicians are willing to give up some clinical autonomy to the pharmacist to enable
delivery of pharmacogenomics in clinical practice. The ability for this to succeed will also be
partially dependent on robust educational and training initiatives that enable the pharmacist to
effectively deliver pharmacogenomic testing. Finally, variability in state-to-state collaborative
practice policies should be examined as a crucial factor in the success of such arrangements.
Physicians in states with more advanced policies will likely be the innovators in advancing the
pharmacist to higher levels of clinical practice, while laggard state policies will require greater
intervention and education on the benefits and possibilities of such arrangements.
To close, these three studies have focused on converging the clinical science of
pharmacogenomics with the discipline of implementation science. We have more deeply
explored this convergence by looking at the foundation concept of sustainability. This work has
great methodological breadth as we utilized review, qualitative, and quantitative/experimental
techniques. Moving forward the hope is that future researchers recognize the potential for
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implementation science as a facilitator of high quality, standardized study designs that address
new and existing issues critical to the sustainability of clinical pharmacogenomics in practice.
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